VICP Registry Case Source Bundle
Canonical URL: https://vicp-registry.org/case/USCOURTS-cofc-1_16-vv-00633
Package ID: USCOURTS-cofc-1_16-vv-00633
Petitioner: Melissa Larson
Filed: 2016-05-27
Decided: 2023-10-02
Vaccine: influenza
Vaccination date: 2013-11-06
Condition: Guillain-Barré syndrome (GBS)
Outcome: denied
Award amount USD: 

AI-assisted case summary:
Melissa Larson, a 36-year-old respiratory therapist, received an influenza vaccine on November 6, 2013, as a condition of her employment. Approximately six weeks later, she presented with severe lower back pain, which was initially diagnosed as a sprain. Shortly thereafter, she developed new symptoms including numbness, facial drooping, shortness of breath, difficulty swallowing, and increasing weakness. A neurologist raised the possibility of Guillain-Barré Syndrome (GBS), and she was hospitalized for monitoring and tests, including a spinal tap which showed slightly elevated protein. Despite these concerns, she was not treated for GBS and her symptoms largely subsided. Her discharge diagnoses included generalized weakness and possible GBS. Over the following year, Larson sought treatment from various specialists for recurring symptoms, with physicians increasingly questioning the GBS diagnosis and considering fibromyalgia as a more likely cause. Her worker's compensation claim for a vaccine injury was denied, and a neurologist opined that a clear diagnosis of GBS could not be made. In October 2014, a neurologist diagnosed her with fibromyalgia, a diagnosis echoed by subsequent medical professionals. Larson was eventually treated for fibromyalgia and returned to work in April 2016. The Special Master denied entitlement, finding that Larson failed to demonstrate by a preponderance of the evidence that she suffered from GBS, citing inconsistencies with typical GBS presentations, normal EMG/NCS results, and her recovery without GBS-specific treatment. The Court of Federal Claims affirmed this decision, agreeing that Larson did not meet her burden of proof for GBS. The Court also noted that Larson's claim had evolved from an initial fibromyalgia diagnosis to a GBS-focused claim, with fibromyalgia later presented as a sequela of GBS, and found no basis to remand for consideration of a standalone fibromyalgia claim.

Theory of causation field:
Off-Table

Public staged source text:

================================================================================
DOCUMENT 1: USCOURTS-cofc-1_16-vv-00633-1
Date issued/filed: 2023-06-01
Pages: 34
Docket text: PUBLIC DECISION (Originally filed: 4/28/2023) regarding 110 DECISION of Special Master. Signed by Special Master Katherine E. Oler. (emh) Service on parties made.
--------------------------------------------------------------------------------
Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 1 of 34
In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
No. 16-633V
Filed: April 28, 2023
* * * * * * * * * * * * * * * * * * * * * * * * * *
*
*
MELISSA LARSON, TO BE PUBLISHED
*
*
Petitioner, *
*
Guillain-Barré syndrome (GBS);
*
v. * Influenza Vaccine; Decision on
* Entitlement
SECRETARY OF HEALTH AND *
HUMAN SERVICES, *
*
*
Respondent. *
*
* * * * * * * * * * * * * * * * * * * * * * * * * *
John F. McHugh, Law Office of John McHugh, LLC, New York, NY, for Petitioner
Alexa Roggenkamp, U.S. Department of Justice, Washington, DC, for Respondent
DECISION ON ENTITLEMENT1
Oler, Special Master:
On May 27, 2016, Melissa Larson (“Petitioner”) filed a petition for compensation under
the National Vaccine Injury Compensation Program2 alleging that she suffered from fibromyalgia
as result of the influenza (“flu”) vaccination she received on November 6, 2013. Pet. at 1, ECF
No. 1. Without amending her petition, Petitioner subsequently asserted that the flu vaccination she
received caused her to develop Guillain-Barré syndrome (“GBS”). Pet’r’s Pre-Hearing Brief, ECF
1 Because this Decision contains a reasoned explanation for the action taken in this case, it must be made
publicly accessible and will be posted on the United States Court of Federal Claims' website, and/or
at https://www.govinfo.gov/app/collection/uscourts/national/cofc, in accordance with the E-Government
Act of 2002. 44 U.S.C. § 3501 note (2018) (Federal Management and Promotion of Electronic Government
Services). This means the Decision will be available to anyone with access to the internet. In accordance
with Vaccine Rule 18(b), Petitioner has 14 days to identify and move to redact medical or other information,
the disclosure of which would constitute an unwarranted invasion of privacy. If, upon review, I agree that
the identified material fits within this definition, I will redact such material from public access.
2 The Vaccine Program comprises Part 2 of the National Childhood Vaccine Injury Act of 1986, Pub. L.
No. 99-660, 100 Stat. 3758, codified as amended at 42 U.S.C. §§ 300aa-10 through 34 (2012) (“Vaccine
Act” or “the Act”). Individual section references hereafter will be to § 300aa of the Act (but will omit that
statutory prefix).

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 2 of 34
No. 91 at 1-2, 8; Tr. at 177. For the reasons set forth below, I find that Petitioner has not
preponderantly demonstrated that she had GBS. Accordingly, her petition is dismissed.
I. Procedural History
Petitioner filed her petition on May 27, 2016. ECF No. 1 (“Pet.”). Petitioner filed medical
records on June 15, 2016, September 29, 2016, and October 25, 2016. ECF Nos. 8, 9, 17, 19.
Respondent filed his Rule 4(c) report recommending against compensation on January 12, 2017.
ECF No. 23.
The parties filed expert reports from Dr. Dimitrios Karussis (Ex. 15), Dr. Yehuda
Shoenfeld (Ex. 31), and Dr. Timothy Vartanian (Ex. A).
On September 18, 2019, I posed three questions to the parties’ experts. ECF No. 60.
Petitioner engaged Dr. Marcel Kinsbourne as an expert after her attempts to contact Dr. Karussis
were unsuccessful. ECF No. 67. Dr. Shoenfeld responded to my questions on December 12, 2019.
Ex. 74 (“Shoenfeld Answers”). Dr. Kinsbourne responded to my questions on December 13, 2019.
Ex. 90 (“Kinsbourne Answers”). Dr. Vartanian responded to my questions on December 19, 2019.
Ex. C (“Vartanian Answers”).
I held an entitlement hearing on November 8, 2021, where I heard testimony from
Petitioner and from Drs. Shoenfeld, Kinsbourne, and Vartanian. See Minute Entry dated November
8, 2021. The parties filed post-hearing briefs over the following six months. Pet’r’s Post-Hearing
Brief, ECF No. 104; Resp’t’s Post-Hearing Brief, ECF No. 107; Pet’r’s Reply Brief, ECF No. 108.
On May 26, 2022, the parties filed a joint status report confirming that the record was complete
for a decision on entitlement. ECF No. 109. This matter is now ripe for adjudication.
II. Medical History
Prior to November 2013, Petitioner was generally in good health. Petitioner suffered from
mild asthma for which she took albuterol as needed. Ex. 9 at 41. She also experienced anxiety and
panic attacks, for which she had been prescribed Xanax and Belviq. Id.; Ex. 3a at 26.
On November 6, 2013, Petitioner, then aged 36 years, received the allegedly causal flu
vaccine at Aurora Healthcare, where she worked as a respiratory therapist. Ex. 2 at 2; Tr. at 8.
Forty-one days later, on December 17, 2013, Petitioner saw Julia Johnson, DO, in the
emergency room reporting that she had begun experiencing sharp pain in her lower back the
previous evening while sitting on her bed playing with her 18-month-old child. Ex. 3a at 25.
Petitioner denied numbness, tingling, and other symptoms. Id. Examination revealed “decreased
range of motion, tenderness, pain and spasm” with “no bony tenderness” in her lumbar spine. Id.
at 28. Dr. Johnson diagnosed lumbosacral joint sprain and prescribed diazepam, ibuprofen, and
Percocet. Id. at 29.
On December 18, 2013, Petitioner followed up with Shashi Bhushan, MD, her regular
physician. Ex. 9 at 44. Petitioner reported continuing lower back pain, but denied trauma, radiating
2

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 3 of 34
pain, and bowel and urinary incontinence. Id. at 45. Petitioner’s strength and reflexes were normal.
Id. Dr. Bhushan noted that Petitioner experienced pain on flexion and extension and was “unable
to be on the examination table.” Id. Dr. Bhushan diagnosed Petitioner with low back pain likely
resulting from musculoskeletal strain, administered a Solu-Medrol injection, and prescribed
prednisone, diclofenac, and Flexeril. Id.
When her back pain did not improve, Petitioner saw Dr. Bhushan again on December 20,
2013. Dr. Bhushan ordered an MRI, which took place that same day. Ex. 9 at 47; Ex. 3a at 10. The
MRI revealed minimal anterolisthesis3 on Petitioner’s L4 and L5 vertebrae, with normal alignment
in the rest of her lumbar spine. Id. The MRI also revealed mild to moderate disc protrusion at L4
and L5, desiccation of the disc between L4 and L5, and narrowing of the spinal canal. Id.
Petitioner saw Dr. Bhushan again on December 24, 2013, complaining that her back pain
was “excruciating” and “7/10 in intensity”. Ex. 9 at 48. Petitioner denied tiredness, headache, focal
weakness, and sensory changes. Id. Dr. Bhushan referred Petitioner to a neurosurgeon. Id. at 49.
On December 27, 2013, Petitioner saw neurologist John Pidgeon, MD, reporting that she
felt “numb and weak all over” and that, two to three days prior to her visit, she had begun
experiencing generalized paresthesias. Ex. 4 at 5. She also reported facial drooping on both sides,
shortness of breath during the night, difficulty swallowing, and progressively worsening weakness.
Id. During her appointment, Petitioner had difficulty rising from a sitting to a standing position
and was unable to raise her arms above shoulder level. Id. Dr. Pidgeon noted that Petitioner
exhibited facial diplegia,4 symmetric 1+ reflexes, full extraocular movements, dysarthria,5 and 4-
/5 strength bilaterally in her neck and upper extremities. Id. at 6. Dr. Pidgeon expressed concern
that Petitioner may have GBS and noted that this “could be a reaction to the flu shot that she
received.” Id. He referred Petitioner back to the emergency room out of concern that her condition
might worsen, necessitating a ventilator. Id.
In the emergency room that same day, Petitioner saw Thulasiraman Ravichandran, MD,
reporting that she felt like she had pins and needles from her feet to her lower chest and that she
felt numbness and tingling in both hands. Ex. 5a at 77. Petitioner reported difficulty breathing,
slurred speech, and a feeling that her body was heavy (“like jell-O”). Id. Dr. Ravichandran noted
that Petitioner exhibited no facial weakness and no plegia and that her reflexes were symmetrical
and “quite brisk.” Id. He referred Petitioner to the Neuro ICU for close monitoring for acute GBS
3 Anterolisthesis (also known as spondylolisthesis) is “forward displacement (olisthy) of one vertebra over
another, usually of the fifth lumbar over the body of the sacrum, or of the fourth lumbar over the fifth,
usually due to a developmental defect in the pars interarticularis.” DORLAND’S MEDICAL DICTIONARY
ONLINE (hereinafter “DORLAND’S”), https://www.dorlandsonline.com/dorland/definition?id=46742 (last
visited on Apr. 19, 2023).
4 Diplegia is “paralysis affecting like parts on both sides of the body.” DORLAND’S, https://www.
dorlandsonline.com/dorland/definition?id=14328 (last visited on Apr. 19, 2023).
5 Dysarthria is “a speech disorder consisting of imperfect articulation due to loss of muscular control after
damage to the central or peripheral nervous system.” DORLAND’S, https://www.dorlandsonline.com/
dorland/definition?id=15144 (last visited on Apr. 19, 2023).
3

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 4 of 34
and ordered an electromyography nerve conduction study and a spinal tap. Id. at 78. Petitioner
underwent an MRI of her cervical spine, which revealed a “[s]mall right paracentral disc
protrusion” at C5-C6 and a “subtle increased enhancement on the surface of the lower thoracic
spinal cord and conus,” possibly representing an inflammatory or infectious process. Ex. 5b at 98-
99. Petitioner also underwent an MRI of her brain, which was unremarkable. Id. at 100. Analysis
of her cerebrospinal fluid (CSF) showed slightly elevated protein (57 mg/dL, where the reference
range is 15-45 mg/dL). Ex. 5c at 24. The nerve conduction study was not performed until March
2014 because Petitioner improved rapidly and there was no one available to perform the test during
her hospital stay. Ex. 5a at 70, 78; Ex. 5e at 33.
Petitioner saw Dr. Ravichandran the next day, December 28, 2013. Ex. 5a at 75. He noted
that Petitioner was “much improved,” that her reflexes were brisk, and that she showed no facial
diplegia. Id. Based on her condition, Dr. Ravichandran determined not to begin IVIG treatment or
plasmapheresis unless her condition began to deteriorate. Id. at 76.
That same day, Petitioner had an infectious disease consultation with Francisco Aguilar,
MD. Ex. 5a at 79. Petitioner reported four or five days of diaphoresis6 but denied fever and chills.
Id. at 80. Dr. Aguilar noted that Petitioner had had multiple episodes of stomach flu in October
and November 2013. Id. Dr. Aguilar’s examination revealed some weakness in Petitioner’s
extremities, symmetrical reflexes, and no signs of respiratory failure. Id. Dr. Aguilar’s impression
was that the “presumptive diagnosis [was] possible [GBS].” Id. at 81. Influenza A and B assays
on December 19, 2013, were negative. Id. Petitioner tested negative for Epstein-Barr virus,
cytomegalovirus, toxoplasmosis, tuberculosis, myasthenia gravis, enterovirus, Lyme, HIV,
antinuclear antibody, campylobacter jejuni (“c. jejuni”) IgG, and West Nile virus. Id. at 53-68.
On December 29, 2013, Petitioner saw Dr. Ravichandran again, who noted that Petitioner’s
numbness was resolving and was then mostly in her feet. Ex. 5a at 94. Petitioner was able to walk
without tachycardia or dysautonomia. Id. Petitioner exhibited normal range of motion in her
shoulders and legs and showed no facial symptoms. Id. Dr. Ravichandran noted that Petitioner had
a urinary tract infection at the time of this visit and that her symptoms were “related to post-flu
shot demyelinating neuropathy.” Id. at 95.
Petitioner was discharged from the hospital on December 31, 2013. Ex. 5a at 69-70. Her
condition had improved “fairly rapidly,” and IVIG and plasma exchange were never administered.
Id. at 70. Petitioner’s diagnosis at the time of discharge was generalized weakness and possible
GBS. Id. at 69.
On January 6, 2014, Petitioner saw Dr. Pidgeon for a follow-up, complaining of
uncomfortable pins and needles sensations, paraphasic errors,7 and weakness. Ex. 4 at 11.
6 Diaphoresis is “sweating, sometimes specifically that induced artificially.” DORLAND’S, https://www.
dorlandsonline.com /dorland/definition?id=13776 (last visited on Apr. 19, 2023).
7 Paraphasia is “a type of dysphasia in which a person uses wrong words or uses words in wrong and
senseless combinations.” DORLAND’S, https://www.dorlandsonline.com/dorland/definition?id=36908 (last
visited on Apr. 20, 2023).
4

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 5 of 34
Petitioner exhibited facial diplegia but was not dysarthric and was able to walk without difficulty.
Id. She exhibited brisk reflexes in all her extremities. Id. Dr. Pidgeon noted that it would be unusual
for a patient with GBS to have brisk reflexes, especially given that Petitioner’s MRI showed a
possible change in signal in the thoracic spinal cord. Id.
On January 23, 2014, Petitioner saw Dr. Pidgeon again, at which time Dr. Pidgeon’s
diagnosis was GBS. Ex. 4 at 16. Petitioner complained of ongoing fatigue that was preventing her
from returning to her job, as well as paresthesias. Id. at 15-16. Another MRI of Petitioner’s thoracic
spine revealed that the previously identified abnormality was likely benign. Id. at 17. Dr. Pidgeon
noted that Petitioner still exhibited facial diplegia, but that it had improved since her last visit. Id.
He also noted 4+ out of 5 reflexes in all of Petitioner’s extremities. Id.
On February 25, 2014, Petitioner followed up with Dr. Pidgeon. Ex. 4 at 19-23. Dr.
Pidgeon noted that Petitioner was undergoing physical therapy three times per week and daily
occupational therapy, as well as aqua therapy. Id. at 22. Petitioner reported that Gabapentin was
helping with the discomfort related to her paresthesias and that she was also using a TENS unit to
manage her pain. Id. On examination, Petitioner exhibited more facial animation and increased
arm strength and was not dysarthric. Id.
On February 28, 2014, Petitioner saw Kenneth Bortin, MD, for a cardiology consultation.
Ex. 3a at 103-06. Petitioner complained of tachycardia and chest pain over “the past several weeks”
and noted that sharp discomfort in her chest was usually positional and associated with a rapid
heartbeat. Id. at 103. Petitioner denied dizziness, syncope, blurred and double vision, and
dyspepsia.8 Id. at 103-04. Petitioner’s blood pressure at this visit was 110 over 80 and her pulse
was 110. Id. at 105. The examination of Petitioner and her recent EKG were both normal. Id. at
106. Dr. Bortin diagnosed Petitioner with “[a]typical chest pain and tachycardia in the setting of a
recent viral syndrome/[GBS].” Id.
On March 14, 2014, Petitioner was admitted to intensive care for generalized progressive
weakness. Ex. 5e at 6. Petitioner complained of generalized weakness, a “jell-O” feeling,
numbness, and tingling. Id. at 7. Analysis of Petitioner’s CSF revealed minimally elevated
proteins, possibly indicating the presence of chronic inflammatory process. Id.; Id. at 20. Wilson
Cueva, MD, expressed doubt that petitioner had GBS and described her examination as “pretty
benign,” noting that she did have hyperreflexia. Id. at 4-5. Dr. Cueva posited that Petitioner could
be suffering from a chronic inflammatory process or ongoing inflammatory condition. Id. at 5. He
remarked that while Petitioner may have had GBS in December 2013, he did not believe that she
had GBS at the time of his examination in March 2014. Id.
Petitioner’s symptoms improved without resort to IVIG or plasmapheresis. Ex. 5e at 10.
Petitioner was transferred out of intensive care on March 15, 2014, and her neurological
examination on March 16, 2014, was “essentially normal.” Id. at 19. Additional CSF studies were
negative. Id. at 20. Dr. Cueva noted that the bulging in Petitioner’s L5 disc might explain the mild
chronic inflammatory changes in her CSF. Id. Dr. Cuerva observed that Petitioner may have been
8 Dyspepsia is “impairment of the power or function of digestion; usually applied to epigastric discomfort
following meals.” DORLAND’S, https://www.dorlandsonline.com/dorland/definition?id=15263 (last visited
on Apr. 20, 2023).
5

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 6 of 34
experiencing worsening of her residual slight generalized weakness secondary to a systemic
process (upper respiratory infection). Id. Dr. Cuerva approved Petitioner to be discharged home.
Id.
On March 17, 2014, Petitioner saw Elizabeth Marriott, MD, for a neurology consultation.
Ex. 5e at 26-28. Dr. Marriott noted that Petitioner had a mild to moderate upper respiratory
infection “for the past few days.” Id. at 26. Examination revealed that Petitioner’s reflexes and
motor strength were intact and her sensory and cerebellar examinations were normal. Id. at 28. Dr.
Marriott noted that the etiology of Petitioner’s symptoms was not clear, but that her condition was
“[c]linically inconsistent with recurrent inflammatory neuropathy.” Id.
On March 18, 2014, Petitioner underwent EMG and NCS, which showed no
electrophysiological evidence of L2-S1 acute/active radiculopathy, lumbosacral plexopathy,
myopathy, entrapment neuropathy, or peripheral polyneuropathy of the bilateral lower extremity.
Ex. 5e at 33. Based on Petitioner’s normal EMG, increased reflexes, and only minimal elevation
in CSF protein, Dr. Marriott’s diagnosis was subjective weakness and paresthesias. Id. at 33-34.
Dr. Marriott noted that Petitioner’s symptoms may have resulted from a subclinical process and
referred Petitioner for outpatient follow-up. Id. at 34.
Petitioner returned to her primary care provider, Dr. Bhushan, on April 16, 2014,
complaining of an unsteady gait, forgetfulness, and weakness in her legs. Ex. 9 at 53. Dr. Bhushan
diagnosed neurological symptoms and opined that Petitioner’s symptoms were likely somatoform.
Id.
On April 22, 2014, Petitioner saw occupational health specialist Christopher Kolimas, MD,
for a fit for duty/disability evaluation. Ex. 4 at 33. Petitioner indicated that her condition had started
to improve since her hospitalization in March 2014. Id. at 35. She reported symptoms including
facial twitching; diminished sensation in her face, left arm, and left leg; heaviness and weakness
in all extremities; dysarthria; difficulty speaking, including choosing words; double vision;
weakness in both hands (more severe on the left side than the right); trouble walking on uneven
surfaces and stairs; and weakness and paresthesias in her legs such that she was unable to walk or
stand for more than 10 minutes. Id. Petitioner reported that she was unable to do household chores
for more than a few minutes at a time or drive for more than 15 minutes at a time. Id. at 36. She
also reported that she had trouble performing calculations and with fine motor skills. Id. Dr.
Kolimas noted that Petitioner’s speech was slow and that she had difficulty finding and articulating
words. Id. at 37. Petitioner was able to stand up from a seated position without assistance, but she
walked with a limp and had trouble walking on her heels, exhibiting more weakness on her left
side. Id. She was able to squat and rise, but struggled with rapid alternating movements, more
slowly on the left side than the right. Id. Dr. Kolimas noted mild weakness distally involving ankle
dorsiflexion and grip strength which was more severe on Petitioner’s left side. Id. at 38. Petitioner’s
reflexes were brisk. Id. Notes from other providers indicated that Petitioner experienced persistent
bilateral upper extremity weakness and incoordination and had difficulty completing everyday
tasks. Id. at 40. Dr. Kolimas concluded that Petitioner was unable to perform many of her job
functions as a respiratory therapist. Id. at 42.
6

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 7 of 34
On May 19, 2014, Petitioner saw neurologist Barend Lotz, MD, for a neuromuscular
consultation. Ex. 11 at 2-7. Dr. Lotz noted that at first, he had difficulty obtaining an accurate
history from Petitioner. Id. at 4. Petitioner indicated that her legs had become “completely
paralyzed” in December 2013 and that she experienced new arm weakness about a week later. Id.
Dr. Lotz noted that Petitioner’s records showed that she had never lost reflexes, that her CSF
protein had been slightly elevated with no pleocytosis,9 that her EMG was normal, and that
degenerative changes in her L5-S1 may have explained her back pain. Id. Dr. Lotz noted that
Petitioner did not display any weakness in either her arms or legs and was able to walk on her heels
and toes without difficulty. Id. He further noted that Petitioner claimed she could not move her
toes up or down, but that on exam, “she could do this completely normally.” Id. Petitioner did
exhibit a limping gait “for unknown reasons,” but reported that she was not in pain. Id. at 5. Dr.
Lotz’s diagnosis was a conversion reaction simulating weakness in the left leg. Id. Dr. Lotz wrote
the following in the medical record:
I spent a lot of time explaining to the patient and her husband that she does not have
Guillain-Barre or Guillain-Barre-like disease. If there was such a disease, it would
have started within 10 days of vaccination because that is when the antibodies are
produced. Her EMG study would have been abnormal. She would have lost her
reflexes, so there is no evidence that she had that. Therefore, I cannot tell them why
she had this disease with paralysis of the arms and legs.
Id.
On June 19, 2014, Petitioner saw Rose Dotson, MD, for a neuromuscular consultation. Ex.
6a at 8-25. Dr. Dotson reviewed Petitioner’s medical records and diagnosed her with subjective
generalized muscle weakness, “give way”. Id. at 8, 24. She noted that Petitioner’s previous
diagnosis of GBS was made “clinically” in spite of there being “no convincing CSF finding” and
no EMG performed at the time of diagnosis. Id. at 24. Dr. Dotson’s specific assessments appear
as follows in the medical record:
Id.
9 Pleocytosis is “presence of a greater than normal number of cells in the cerebrospinal fluid.” DORLAND’S,
https://www.dorlandsonline.com/dorland/definition?id=39556 (last visited on Apr. 20, 2023).
7

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 8 of 34
On July 7, 2014, Petitioner underwent a nerve conduction study which yielded normal
results and no evidence of neuropathic or myopathic process. Ex. 6a at 34.
On August 17, 2014, Petitioner saw Dr. Dotson for a follow up. Ex. 6a at 68-69. Petitioner
complained of tachycardia, generalized weakness, fatigue, orthostatic lightheadedness,
paresthesias, and myalgia. Id. at 68. Dr. Dotson noted that Petitioner’s previous diagnosis of GBS
had been made “without objective evidence.” Id. Petitioner underwent a tilt table test with “mildly
abnormal” results. Ex. 6b at 4. Her neurological examination was normal. Id. at 2. Dr. Dotson’s
assessment was unspecified tachycardia. Id. at 5. When Petitioner returned the following day, Dr.
Dotson diagnosed her with small fiber neuropathy per clinical examination and neuropathic pain.
Id. at 18.
On August 18, 2014, Petitioner underwent a sweat test. Ex. 6b at 15. The results showed
normal volume at all sites with lower relative volume on Petitioner’s forearm. Id.
Petitioner returned to see Dr. Dotson on October 6, 2014, complaining that her pain had
increased and that fatigue was making it difficult to perform household tasks. Ex. 6b at 51. She
also complained of trouble falling and staying asleep and of cognitive slowing and brain fog. Id.
On examination, Petitioner exhibited 14 out of 18 fibromyalgia tender points. Id. at 53. Petitioner’s
autoantibody profile was negative and skin biopsies from her left leg were both normal. Id. at 54-
57. Dr. Dotson diagnosed Petitioner with fibromyalgia with widespread pain, tender points, sleep
disturbance, and cognitive symptoms. Id. at 57. Dr. Dotson noted that there was no objective
support for her prior clinical diagnosis of small fiber neuropathy, and that the prior diagnosis was
in question in light of the findings supporting fibromyalgia. Id.
On November 24, 2013, Petitioner saw Mary Yellick, APNP, reporting that her symptoms
had worsened since the end of October 2014. Ex. 6c at 10. Petitioner complained of fatigue, pain,
trouble falling and staying asleep, and brain fog. Id. Petitioner’s physical examination was
unchanged. Id. at 10-17. NP Yellick continued Petitioner’s prior diagnosis of fibromyalgia. Id. at
17.
On December 10, 2014, Petitioner reported to the emergency room complaining of a
headache, facial numbness on the left side, and weakness in her left arm and left leg. Ex. 3b at 97.
The emergency physician noted that Petitioner’s history was significant for GBS and fibromyalgia
and that she was seeing a neurologist for a “mystery diagnosis.” Id. Petitioner spoke very slowly
and complained of facial paresthesias. Id. at 99. The record notes no focal neurologic deficits. Id.
Petitioner’s heart rate was 77 bpm and her head CT was normal. Id. at 99-100. Petitioner was
advised to follow up with Dr. Dotson. Id. at 101.
On December 18, 2014, Petitioner saw Farzan Mahmood, MD, for a rheumatology
consultation. Ex. 9 at 56-58. Dr. Mahmood’s assessment was chronic pain and fatigue likely due
to fibromyalgia. Id. at 58. He noted that Petitioner also had dysautonomia “which is commonly
seen with fibromyalgia.” Id. In January 2015, Petitioner began taking Savella, which helped
somewhat. Ex. 9 at 59. Petitioner continued to receive treatments over the following months and
Dr. Mahmood cleared her to return to work part time in March 2016. Ex. 10a at 100.
8

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 9 of 34
Petitioner applied for worker’s compensation for her alleged vaccine injury in December
2013 or early January 2014. Ex. 96 at 38 (showing that the insurer had received her claim prior to
January 8, 2014). Neurologist Brian A. Chapman, MD, reviewed her case on behalf of the insurer
and opined that “[a]t this time, no clear diagnosis can be made of Guillain-Barre syndrome.” Id. at
54. Accordingly, Petitioner’s claim for worker’s compensation was denied on March 31, 2014. Id.
at 51. Petitioner also applied for long term disability benefits through her employer, which were
approved on April 17, 2014. Id. at 4. In support of her claim for disability benefits, Petitioner
supplied medical records documenting her inability to work due to her symptoms, particularly
fatigue, weakness, cognitive issues, and pain. Id. at 24.
No further medical records pertinent to this analysis have been filed.
III. Expert Reports and Testimony
A. Petitioner’s Expert – Dimitrios Karussis, MD, PhD
1. Qualifications
Dr. Karussis received his medical degree at Aristotelion University in Greece in 1986 and
his PhD in neuroimmunology at Hebrew University in Israel in 1993. Ex. 16 (“Karussis CV”) at
2. He is board certified in neurology in the European Union and in clinical neurology and
neurology in Israel. Id. at 3. He has been a member of the neurology faculty at Hebrew University
since 1997 and was promoted to full professor in 2014. Id. Dr. Karussis has been the Director of
the Neuroimmunology Unit at Haddassah University Hospital since 2014 and has been the Head
of the Hadassah MS Centre since 2007. Karussis Rep. at 2.
Dr. Karussis’s research interests include topics in neuroimmunology, particularly MS.
Karussis CV at 5-6. He has been a principal investigator in 28 clinical trials related to MS since
the early 1990’s. Id. at 7-9. He also teaches courses in neurology and advises graduate students at
Hebrew University. Id. at 9-11. He is the author of five book chapters and more than 100 peer-
reviewed journal articles in neuroimmunology and neurology, with a particular focus on MS. Id.
at 11-28.
2. Expert Report
Dr. Karussis authored one expert report in this case. Ex. 15 (“Karussis Rep.”). In his report,
he opined that GBS is Petitioner’s correct diagnosis based on her medical records. Id. at 11. He
opined that, while Petitioner did not exhibit elevated protein in her CSF, reduced nerve conduction
velocity on EMG, or loss of deep tendon reflexes, these findings may be absent or “not prominent”
in the early stages of GBS. Id. at 9-10. He further opined that the symptoms Petitioner reported,
including paresthesias, numbness, general weakness, pain in the lower back and extremities, and
facial diplegia “represent the most typical/classical presentations of GBS.” Id. at 10. Dr. Karussis
stated that the change in Petitioner’s diagnosis from GBS to fibromyalgia in 2014 was “puzzling”
and “not based on any new findings.” Id. He also posited that diffuse muscle pain and autonomic
instability, both of which Petitioner experienced, are common to both conditions and might have
caused confusion of the two. Id.
9

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 10 of 34
Dr. Karussis acknowledged that “this is certainly not a very typical case of GBS,” but
nevertheless maintained that GBS rather than fibromyalgia was the most likely diagnosis. Karussis
Rep. at 11. He opined that Petitioner’s lack of neurological symptoms prior to December 2013
makes fibromyalgia less likely because “it would be very peculiar that all these symptoms started
‘by chance’ after the vaccination and without any association with it.” Id.
Dr. Karussis concluded his report by summarizing the link between the H1N1 flu
vaccination and an increased incidence of GBS cases (an additional 1.6 GBS cases for every
1,000,000 people vaccinated). Karussis Rep. at 12. He opined that this data combined with the
timing of the onset of Petitioner’s condition “is very supportive of a causative association.” Id.
B. Petitioner’s Expert – Yehuda Shoenfeld, MD, FRCP
1. Qualifications
Dr. Shoenfeld received his medical degree at Hebrew University in Israel in 1972. Ex. 32
(“Shoenfeld CV”) at 3. He completed his post graduate studies in internal medicine at Tel-Aviv
University in 1978. Id. He presently holds the Laura Schwarz-Kipp Chair for Research of
Autoimmune Diseases at Tel-Aviv University and is the Head of the Zabludowicz Center for
Autoimmune Diseases at Sheba Medical Center, also at Tel-Aviv University. Id. His
responsibilities as an emeritus professor include teaching medical students and advising graduate
students. Shoenfeld Rep. at 2. He also sees patients two days per week. Tr. at 93.
Dr. Shoenfeld’s research interests include cancer and autoimmunity, as well as
autoimmune diseases. Shoenfeld CV at 26-141. Dr. Shoenfeld is the author of 62 books, 158 book
chapters, and 1,982 peer-reviewed journal articles. Id. at 23-141. I recognized him as an expert in
the field of autoimmunity. Tr. at 77-78.
2. Expert Report
Dr. Shoenfeld authored one expert report in this case. Ex. 31 (“Shoenfeld Rep.”). In it, he
concluded that Petitioner’s medical history and the medical literature “support the diagnosis of
[GBS] accompanied by fibromyalgia and chronic fatigue,” and that the flu vaccine most likely
caused Petitioner’s condition by means of molecular mimicry. Id. at 22.
Dr. Shoenfeld noted that the symptoms Petitioner reported were numerous and varying in
intensity over a period of months. Id. at 17-18. He opined that “such a constellation of symptoms
is almost mostly [sic] a snapshot of [GBS].” Id. at 18. Dr. Shoenfeld also noted that one of the
components of the flu vaccine administered in 2013 and 2014 “shares numerous peptide sequences
with 22 human proteins involved in myelin, (de)myelination, and/or axonal neuropathies.” Id. He
added that “the mathematical probability of a pentapeptide occurring at random in two proteins
may be calculated as about 20-5 or 1 in 3,200,000.” Id. He posited that the vaccine could have
caused Petitioner’s GBS by means of molecular mimicry. Id.
Dr. Shoenfeld also addressed Petitioner’s fibromyalgia diagnosis at length. He noted that
Petitioner’s medical records indicate abnormal titers for striational antibodies. Shoenfeld Rep. at
10

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 11 of 34
19. He cited medical literature supporting his theory that “major antigenic targets of striational
antibodies” include titin, Ryanodine receptor, and Kv1.4. Id. at 19-20. He opined that molecular
mimicry may have induced Petitioner’s striational antibodies to attack these three self-antigens,
resulting in progressive weakness, myalgia, and chronic pain, respectively. Id. at 20. Dr. Shoenfeld
also noted that a component of the flu vaccine shares two peptide chains with “the human
membrane magnesium transporter 1, isoform 2.” Id. at 21. He opined that molecular mimicry could
cause immune attack on the magnesium transporter, resulting in an “altered level of cellular
magnesium, a condition that has been repeatedly associated with fibromyalgia, asthma, and
chronic fatigue syndrome.” Id.
3. Response to My Questions
Prior to the entitlement hearing, I posed three questions to the parties’ experts. ECF No.
60. First, I asked when they believe Petitioner developed GBS. Dr. Shoenfeld responded that
Petitioner’s GBS developed “somewhere between December 6, 2013 – December 27, 2013” based
on the sharp, shooting pain Petitioner reported that eventually spread throughout her body.
Shoenfeld Answers at 1.
Second, I asked when each expert believes Petitioner developed fibromyalgia. ECF No.
60. Dr. Shoenfeld responded that this occurred “most probably between December 28, 2013 and
January 7, 2014.” noting that Petitioner’s discharge diagnosis after her December 29-31, 2013
hospital stay was generalized weakness. Shoenfeld Answers at 2. He posited that Petitioner’s facial
diplegia and slurred speech may have been early manifestations of fibromyalgia. Id.
Third, I asked whether each expert believes that the conditions of GBS and fibromyalgia
are related. ECF No. 60. In response, Dr. Shoenfeld cited to medical literature supporting his theory
that the flu vaccine triggered different autoantibodies that attacked different parts of Petitioner’s
nervous system (i.e., large nerves, causing GBS, and small fibers, causing fibromyalgia).
Shoenfeld Answers at 2-3.
4. Testimony
Having reviewed the Petitioner’s medical records, Dr. Shoenfeld testified that he believes
that Petitioner suffered from overlapping GBS and fibromyalgia. Tr. at 78. He explained that
autoimmune diseases are induced in people who are genetically prone to them, meaning that they
“have a very aggressive immune system.” Id. Dr. Shoenfeld testified that women in their child-
bearing years are prone to developing autoimmune diseases and that 83% of immune disease cases
are in this group. Id. He opined that Petitioner developed GBS, “a classical autoimmune disease,”
four to six weeks after vaccination. Id. at 79. He also opined that, with regard to timing of onset,
“there are no rules…Sometimes it may be three weeks. Sometimes it may be even seven weeks...40
days or 42 days, this is an average.” Id.
Dr. Shoenfeld testified that it is common for a patient with one autoimmune disease to
develop more of them. Tr. at 80. He noted that fibromyalgia is an autoimmune disease. Id. He also
noted that Petitioner suffered from tachycardia, which indicates that her autonomic nervous system
11

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 12 of 34
was activated. Id. at 82. Dr. Shoenfeld opined that tachycardia and small fiber neuropathy are
objective signs of autoimmune disease. Id. at 84.
Dr. Shoenfeld addressed the fact that Petitioner’s original diagnosis of GBS was later
changed to fibromyalgia by positing that she developed first the one and then the other. Tr. at 86.
He opined that “[m]any of the cases of [GBS] will eventually follow with fibromyalgia.” Id. He
further posited that it was the flu vaccine, by means of molecular mimicry, that triggered the
parallel autoimmune attack on both large nerves and small fibers that led Petitioner to develop
GBS and fibromyalgia in a “natural progression.” Id. at 91.
On cross-examination, Dr. Shoenfeld acknowledged that, while he has seen many patients
with GBS and fibromyalgia over the course of his career, he has recently begun seeing patients
only two days per week rather than full-time. Tr. at 93. Dr. Shoenfeld also acknowledged that,
based on Petitioner’s CSF protein analysis, nerve conduction studies, and deep tendon reflex
exams, Drs. Lotz, Dotson, and Cueva declined to diagnose Petitioner with GBS. Id. at 103-04. He
nevertheless maintained that Petitioner had GBS because abnormal findings as to these diagnostic
tests are not required to diagnose GBS. Id. at 101. He also noted that Petitioner had elevated
albumin in her CSF that may indicate GBS and that was not explained by any other diagnosis. Id.
at 102.
To conclude, Dr. Shoenfeld reiterated his theory that the flu vaccine, by means of molecular
mimicry, hyperstimulated Petitioner’s immune system, thereby inducing an autoimmune reaction.
Tr. at 106. As a result, he opined, Petitioner’s immune system attacked the cells of her central and
peripheral nervous systems, her small fibers, and the GPCR receptors of her autonomic nervous
system. Id. Initially, Petitioner exhibited the signs and symptoms of GBS, and by a single
continuing process of molecular mimicry, Petitioner recovered from GBS and developed parallel
fibromyalgia, from which she still suffers today. Id. at 106-08.
C. Petitioner’s Expert - Marcel Kinsbourne, MD
1. Qualifications
Dr. Marcel Kinsbourne is board certified in pediatrics. Ex. 91 (“Kinsbourne CV”) at 2. He
received his medical degree at Oxford University in England in 1955, and he has been licensed to
practice medicine in North Carolina since 1967. Id. at 1-2. From 1967 to 1974, Dr. Kinsbourne
served as an associate professor in pediatrics and neurology and a senior research associate at Duke
University Medical Center before holding a series of academic positions, including professorships
in pediatrics, neurology, and psychology. Id. at 2. His clinical experience includes serving as a
senior staff physician in Ontario, Canada, from 1974–1980, and a clinical associate in neurology
at Massachusetts General Hospital from 1981–1991, although (as noted in other cases) many years
have passed since he regularly saw patients. Pope v. Sec’y of Health & Hum. Servs., No. 14–078V,
2017 WL 2460503, at *8 (Fed. Cl. Spec. Mstr. May 1, 2017). He has not personally studied the
immunologic issues raised by theories claiming vaccine causation and lacks specialization in the
field of peripheral neuropathies (although his general neurologic expertise rendered him competent
to discuss such matters). Dr. Kinsbourne has testified as an expert witness in the Vaccine Program
since the Program began, but his clinical practice ended in the mid-1990’s. Tr. at 40. I recognized
12

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 13 of 34
Dr. Kinsbourne as an expert in neurology. Id.
2. Response to My Questions
Dr. Kinsbourne responded to the three questions that I posed to the parties’ experts. First,
I asked when each expert believes Petitioner developed GBS. ECF No. 60. Dr. Kinsbourne
responded that Petitioner developed GBS on December 16, 2013. Kinsbourne Answers at 1. He
opined that Petitioner’s severe lower back ache was the onset of her GBS. Id. He cited medical
literature finding that “[p]ain signals the onset of GBS in about one third of cases.” Id.
Second, I asked when each expert believes Petitioner developed fibromyalgia. ECF No.
60. He responded that he does not believe that she ever developed fibromyalgia. Kinsbourne
Answers at 1. He noted that diagnostic criteria exist for fibromyalgia, but that none of Petitioner’s
providers ever applied them. Id. He opined that generalized pain and weakness are not enough to
support a diagnosis of fibromyalgia. Id.
Finally, I asked whether each expert believes that GBS and fibromyalgia are related. ECF
No. 60. Dr. Kinsbourne replied that he does not. Kinsbourne Answers at 1. He noted that pain and
weakness are symptoms of both conditions, and that both may involve small fiber damage. Id. at
1-2. He opined that he knew of no evidence to suggest that these conditions are related, “let alone
that they might substitute for one another in the course of an illness or even both occur at much
the same time.” Id. at 2.
3. Testimony
Dr. Kinsbourne testified at the entitlement hearing on November 8, 2021. He began his
testimony by noting that he had reviewed Dr. Karussis’s expert report and agreed with the latter’s
opinion. Tr. at 37. He later clarified that he believes that Petitioner has GBS and that the flu vaccine
triggered her condition. Id. at 51.
Dr. Kinsbourne opined that Petitioner’s GBS had begun with the severe lower back pain
she reported in December 2013, and that this is “a really common way [for GBS] to begin.” Tr. at
40-41. He also noted that Petitioner’s reported feelings of having cinder blocks hanging from her
limbs occurred close in time to the low back pain, and that the weakness and low back pain that
she described are “a very typical onset symptomatically for [GBS].” Id. at 41.
Dr. Kinsbourne opined that facial diplegia is “uniquely found in [GBS] in this particular
context” and “occurs in more than half of all GBS cases.” Tr. at 41. He stated that he knew of “no
other alternative explanation, no other disease, that would have the kind of acute onset of
weakness, including weakness of the face; no alternative to GBS as a diagnosis for what happened
to her.” Id.
Dr. Kinsbourne testified that the timing of the onset of Petitioner’s condition at 40 days
after vaccination was within acceptable limits for medically establishing causation. Tr. at 42.
Dr. Kinsbourne opined that Petitioner alleges a pain syndrome. Tr. at 44. He noted that the
13

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 14 of 34
pain in Petitioner’s back and legs led to her exhibiting an antalgic gait, meaning that she
unconsciously modified the way she walked in order to minimize pain. Id. Dr. Kinsbourne opined
that the bulging disc in Petitioner’s spine would not explain the pain or weakness that she
experienced. Id.
Dr. Kinsbourne next addressed the medical records indicating that Petitioner suffered from
an unidentified gastrointestinal illness in November 2013 just before Thanksgiving. Tr. at 45. He
noted that there is a known association between c. jejuni infection and the development of GBS.
Id. He noted that Petitioner was not treated for this illness, and so was not tested for c. jejuni until
she was admitted to the hospital in December 2013, at which time the test was negative. Id. He
opined that, while it is not impossible that c. jejuni caused Petitioner’s GBS, the record contains
insufficient evidence to say that this is what occurred. Id.
Dr. Kinsbourne next addressed the change in Petitioner’s diagnosis from GBS to
fibromyalgia. He referred to this as an “unusual course of events” and opined that Petitioner had
“a really rather straightforward, though mild, GBS onset” and that fibromyalgia “is really not that
kind of disease at all.” Tr. at 46. He did acknowledge that the change in diagnosis is understandable
to an extent because Petitioner never lost her reflexes. Id. Dr. Kinsbourne noted that loss of reflexes
affects “the great majority of people with GBS.” Id. He cited medical literature finding that about
10 percent of patients with GBS do not lose their reflexes, and that some even have exaggerated
reflexes. Id. at 47; Yuki, et al., Guillain-Barré syndrome associated with normal or exaggerated
tendon reflexes, 259 J. NEUROL. 1181-90 (2012) (filed as Ex. 19) (“Yuki”). He opined that “there
was no affirmative evidence for fibromyalgia” in the record. Tr. at 47. Dr. Kinsbourne posited that
the burning pain that Petitioner reported in her legs was caused by small nerve fiber damage caused
by GBS. Id. at 47-48. He noted that about half of GBS cases involve small fiber damage, and many
have it for a long period of time. Id. at 48. Dr. Kinsbourne noted that Petitioner’s skin biopsy did
not show small fiber damage, but nevertheless opined that she suffered small fiber damage because
“you can only biopsy one or two points in the skin, not the skin of the whole body.” Id. at 49.
Dr. Kinsbourne testified that the duration of pain that Petitioner reported, approximately
three years, is not unusual in GBS cases. Tr. at 49. He noted that the course of GBS involves an
acute autoimmune attack followed by a period of residual symptoms, and that the length of time
involved “varies enormously from person to person.” Id. He testified that chronic inflammatory
demyelinating polyneuropathy (“CIDP”) is thought to be a chronic version of GBS and that he
does not believe that Petitioner has CIDP. Id.
On cross-examination, Dr. Kinsbourne acknowledged that he is no longer seeing patients,
and that during his time as a clinician, he saw many GBS patients, but no fibromyalgia patients.
Tr. at 52-53.
Dr. Kinsbourne also disagreed with the conclusion that Petitioner’s CSF analysis was
normal. Tr. at 55. He opined that protein in “the CSF was elevated and it was elevated at the level
that’s very typical in fairly early GBS.” Id. at 55-56. He reiterated his opinion that the fact that
Petitioner never lost her reflexes “undermined [her providers’] confidence” in the GBS diagnosis
because they were unaware of the literature suggesting that some GBS patients never lose their
reflexes, and some indeed have exaggerated reflexes. Id. at 58; Yuki. Dr. Kinsbourne posited that
14

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 15 of 34
providers who diagnosed fibromyalgia but did not see Petitioner until after onset of her condition
did not realize that the onset was inconsistent with fibromyalgia. Id. at 59. Rather, he opined that
what appeared to be symptoms of fibromyalgia were in fact “residual injuries caused by the acute
but mild and brief GBS attack.” Id. at 59-60.
Dr. Kinsbourne went on to explain that his assessment of Petitioner’s GBS case as “mild”
was based in part on the fact that she recovered on her own without resort to IVIG or
plasmapheresis. Tr. at 61.
With regard to diagnosis of GBS in general, Dr. Kinsbourne opined that CSF protein
analysis, EMG, and deep tendon reflex exam are appropriate tests. Tr. at 68. He opined that,
because there is variation according to the stage and severity of the disease, there is no specific
protein level in the CSF that would indicate a patient does or does not have GBS. Id. He opined
that the CSF is typically normal in the first week of the GBS disease process and that it typically
rises in the second week. Id. He testified that Petitioner’s CSF analysis was done on her admission
to the hospital roughly 10 days after onset, and that the results were what he would have expected
given the stage and severity of her case. Id.
Dr. Kinsbourne also stated that the fact that Petitioner’s EMG was normal does not change
his opinion that Petitioner had GBS. Tr. at 69. He opined that, because Petitioner had a mild case
of GBS that did not require treatment, he did not find it surprising that the EMG was not diagnostic.
Id. Dr. Kinsbourne explained that GBS onset can be sudden and that the acute autoimmune attack
phase typically lasts about four weeks, after which the damage to the nervous system “can result
in handicaps that last for years, as in this case.” Id. at 70. Dr. Kinsbourne posited that Petitioner’s
EMG may have been normal because the acute autoimmune attack phase of the disease process
had already subsided. See id. at 69.
Dr. Kinsbourne opined that it is possible that Petitioner had fibromyalgia at some point.
Tr. at 71. He added that “[a]nyone could have it at any time” and that it is “a very common
condition.” Id. He emphasized that facial diplegia is very typical in cases of GBS and not at all
consistent with fibromyalgia. Id. at 74. He went so far as to opine that facial diplegia is enough on
its own to clinically diagnose GBS. Id. Based on the timeline of Petitioner’s symptoms, Dr.
Kinsbourne posited that the acute autoimmune attack phase of her GBS ended around the end of
January or beginning of February 2014. Id. at 72.
Finally, Dr. Kinsbourne responded to Dr. Vartanian’s testimony that Petitioner’s initial
headache was likely the result of an annular tear. Tr. at 172-74. He remarked that this explanation
was “appealing,” but was never investigated. Id. at 173-74. He concluded that it was possible, but
that he maintained his opinion that the flu vaccine caused Petitioner’s condition. Id. at 173.
D. Respondent’s Expert – Timothy Vartanian, MD, PhD
1. Qualifications
Dr. Vartanian is a board-certified neurologist who subspecializes in the research and care
of patients with inflammatory demyelinating diseases. Ex. B at 1 (hereinafter “Vartanian CV”).
15

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 16 of 34
Dr. Vartanian taught at Harvard Medical School from 1992-2009 and is currently a professor of
neurology and neuroscience at Weill Cornell Medical College of Cornell University. Id. at 2. He
is the attending neurologist at New York Presbyterian Hospital; Chief Scientist at Neurogen
Research Foundation; and Director of the Judith Jaffe Multiple Sclerosis Center at Beth Israel
Deaconess Medical Center. Id. at 2-3,7. Dr. Vartanian has published over 60 peer-reviewed papers
and is a peer editor for many publications, some of which include Journal of Cell Biology, Journal
of Neuroscience, Brain, Developmental Neuroscience, and Annals of Neurology. Id. at 11-19.
I recognized Dr. Vartanian as expert in neurology, biochemistry, molecular biology and
autoimmune demyelinating diseases. Tr. at 116.
2. Expert Report
In his expert report, Dr. Vartanian opined that “the clinical record does not support a
diagnosis of GBS for multiple reasons.” Ex. A (“Vartanian Rep.”) at 12. He summarized his
reasons as follows: (1) Petitioner’s clinical presentation is not typical of GBS because she never
lost her reflexes; (2) clinical features such as sensory level are unusual for GBS; (3) Petitioner’s
EMG and NCS were normal even when she was still symptomatic; (4) she had only mildly elevated
protein in her CSF; (5) Dr. Dotson had opined that the GBS diagnosis was made without objective
evidence. Id.
Dr. Vartanian noted that alternative diagnoses of fibromyalgia and small fiber neuropathy
had been proposed. Vartanian Rep. at 12. He noted that “small fiber neuropathy is associated with
chronic metabolic and inflammatory diseases.” Id. He opined that “[t]here is no epidemiological
association between distal small fiber neuropathy and influenza vaccination.” Id. at 13.
Dr. Vartanian next responded to points made by Dr. Karussis in his expert report. Dr.
Vartanian disagreed with Dr. Karussis’s observation that Petitioner’s medical records showed
reduced nerve conduction velocity. Vartanian Rep. at 15. He argued instead that Petitioner’s
EMG/NCS was normal and was performed while she was symptomatic. Id.
Dr. Vartanian next responded to Dr. Karussis’s observation that the change in diagnosis
from GBS to fibromyalgia was “puzzling.” Vartanian Rep. at 15-16. Dr. Vartanian observed that
“[t]he diagnosis of fibromyalgia may or may not be supported but I can certainly see why it was
proposed.” Id. at 16.
Dr. Vartanian disagreed with Dr. Karussis’s opinion that Petitioner’s autonomic nervous
system was involved in her condition. Vartanian Rep. at 16. He argued that “there was minimal
autonomic dysfunction” and that “most of the testing was normal.” Id.
Dr. Vartanian next responded to points made by Dr. Shoenfeld in his expert report. In
response to Dr. Shoenfeld’s observation that GBS is a demyelinating polyneuropathy, Dr.
Vartanian noted that “[s]ome demyelinating polyneuropathies are included in the spectrum of GBS
but not all demyelinating neuropathies are GBS.” Vartanian Rep. at 17.
Dr. Vartanian next responded to Dr. Shoenfeld’s comment that it was unclear why
16

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 17 of 34
Petitioner’s providers changed her diagnosis from GBS to fibromyalgia. Vartanian Rep. at 17. Dr.
Vartanian noted that the “consideration of fibromyalgia over GBS was based on clinical
presentation, exam, and the absence of a significantly high elevation in CSF protein.” Id.
Dr. Vartanian disagreed with Dr. Shoenfeld’s opinion that components of the flu vaccine
share several peptides with proteins in myelin, and that this substantiates Petitioner’s GBS
diagnosis. Vartanian Rep. at 20. Dr. Vartanian opined that this logic contains “two fundamental
flaws.” Id. First, he stated that given the large number of flu vaccine doses administered each year,
we would expect to see a high incidence of vaccine-induced GBS if there were an immunologically
significant number of shared epitopes. Id. Second, Dr. Vartanian noted “the idea that identity of
five or six amino acids, sequential or non-sequential, with a putative antigen is sufficient evidence
for a molecular mimic fails on biologic stringency.” Id. He cited medical literature indicating that
identity of short amino acid chains is merely a matter of chance. Id. at 21 (citing Silvanovich, et
al., The Value of Short Amino Acid Sequence Matches for Prediction of Protein Allergenicity,
90(1) TOXICOLOGICAL SCI. 252-58 (2006) (filed as Ex. V)).
3. Response to My Questions
In response to the questions I posed to the parties’ experts (ECF No. 60), Dr. Vartanian
reiterated his opinion that Petitioner’s clinical presentation does not support a diagnosis of GBS.
Vartanian Answers at 1. He again noted that Petitioner’s reflexes were brisk and intact, the
presence of a sensory level, and normal EMG and NCS months after clinical onset all indicated
that she did not have GBS. Id.
4. Testimony
Dr. Vartanian testified at the entitlement hearing on November 8, 2021. He began by
opining that Petitioner did not have GBS. Tr. at 118. He went on to explain that the general
approach to GBS diagnosis involves three criteria: (1) characteristic clinical presentation, (2)
characteristic CSF findings, and (3) a characteristic EMG nerve conduction study. Id. He opined
that none of these criteria are met in Petitioner’s case. Id.
With regard to Petitioner’s diagnosis of fibromyalgia, Dr. Vartanian testified that the record
does not definitively establish that Petitioner had fibromyalgia, but that it is the most likely
diagnosis because it is “the most fitting with her constellation of symptoms.” Tr. at 118-19.
Dr. Vartanian opined that the sudden, acute low back pain Petitioner experienced on
December 16, 2013, was in fact not related to her condition, be it GBS, fibromyalgia, or small
fiber neuropathy. Tr. at 119-20. He noted that low back pain is not uncommon in cases of GBS,
but that it is typically a “dull, aching pain” rather than an “acute, sharp, lancinating pain.” Id. at
120. He also testified that Petitioner’s pain onset occurred “in a characteristic setting for acute
lower back pain [or] strain, which was physical activity.” Id. Dr. Vartanian went on to note that
Petitioner’s December 20, 2013, MRI showed an annular tear in the L4-L5 disc, which he opined
would explain the pain she experienced beginning on December 16. Id. at 120-21. Dr. Vartanian
explained that the annulus is the thick, fibrous capsule surrounding the disc and that physical
activity can cause the annulus to rupture and the disc to extrude. Id. at 121. Such a rupture and
17

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 18 of 34
extrusion can be extremely painful. Id. Dr. Vartanian opined that Petitioner’s “clinical presentation
was characteristic of a disc rupture, an annular tear.” Id. at 122. He added that the MRI on
December 20 was “fully diagnostic.” Id. at 123.
Dr. Vartanian testified that in Petitioner’s case initially, “the working diagnosis was GBS.”
Tr. at 124. He opined that “in medicine…this is extremely common…based on that constellation
of symptoms and findings, there is a working diagnosis and maybe other alternative
diagnoses…commonly called differential diagnoses.” Id. He noted that GBS was never confirmed.
Id. at 125.
Dr. Vartanian testified that it is significant that Petitioner never lost her reflexes. Tr. at 125.
He added that loss of reflexes is characteristic, “almost pathognomonic,” in most GBS cases. Id.
He opined that “[t]he fact that reflexes remained present throughout her clinical course…is not
consistent with the vast majority of GBS.” Id. at 125-26.
Dr. Vartanian also opined that Petitioner’s only minimally elevated CSF protein is
significant. Tr. at 126. He explained that in GBS cases, CSF protein is typically normal or mildly
elevated for the first week after onset and becomes “quite high” as the disease progresses,
approaching 80-120. Id. He noted that Petitioner’s CSF protein analysis was done when she was
in “an active state of being symptomatic” and that the results were only mildly elevated. Id. at 127.
Dr. Vartanian opined that disc rupture and enhancement of the meninges, both of which Petitioner
experienced, can also cause slight elevation in CSF protein; he further highlighted that several of
Petitioner’s treating physicians remarked that the CSF protein was not significantly elevated such
that it would support a GBS diagnosis. Id.
Dr. Vartanian next addressed Petitioner’s EMG nerve conduction results. Tr. at 128. He
opined that these “were completely normal at a time when she was extremely symptomatic.” Id.
He disagreed with Dr. Kinsbourne’s opinion that Petitioner could have a normal EMG at this stage
of her condition and still have GBS, saying that the results “necessarily need to be abnormal…if
[GBS] was the explanation for her disease.” Id. He later disagreed with Dr. Kinsbourne’s theory
that Petitioner’s EMG results were normal because she had a mild case of GBS, pointing out that
if her case were so mild as to be “clinically irrelevant,” that would not explain why the symptoms
she experienced were not mild. Id. at 148.
Dr. Vartanian also found the fact of Petitioner’s improvement without resort to IVIG or
plasmapheresis significant. Tr. at 128-29. He opined that GBS is a progressive illness that “tends
to persist or progress in the absence of treatment.” Id. at 128. He added that, while cases of
spontaneous remission have been known, “no one would leave a bona fide case of GBS untreated
in this modern era.” Id. at 128-29. He reiterated his opinion that Petitioner did not have GBS,
adding that “you wouldn’t make a diagnosis of GBS if all of the criteria that the neurologic
community uses to make a diagnosis of GBS are all normal.” Id. at 129-30.
Dr. Vartanian did acknowledge that Petitioner’s initial clinical presentation was concerning
and that her treating physicians were right to suspect and test for GBS. Tr. at 130. He noted that
“numerous neurologic experts…felt the diagnosis of GBS did not fit at all, and this is when other
things were raised such as small fiber neuropathy and fibromyalgia.” Id. at 131.
18

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 19 of 34
While maintaining his position that Petitioner did not have GBS, Dr. Vartanian declined to
opine on what the correct diagnosis was. Tr. at 136. He noted that Petitioner had a gastrointestinal
illness in November 2013. Id. at 137. Although her antibody test for c. jejuni in December of that
year was negative, he noted that conventional tests for c. jejuni sometimes fail to detect it. Id. He
testified that the two primary issues with implicating a vaccine as having caused a neurological
illness are “plausible biologic evidence that that process actually exists in these patients, and
relevant timing.” Id. at 138. He stated that he was unaware of any epidemiological data associating
the flu vaccine with fibromyalgia. Id. at 140.
Dr. Vartanian next addressed the issue of the timing of onset of Petitioner’s condition. Tr.
at 143-44. He was unequivocal in his opinion that the low back pain Petitioner experienced on
December 16, 2013, was caused by the annular tear in her L4-L5 disc. Id. He added that the onset
of symptoms of fibromyalgia was unclear from the record. Id. at 143. Maintaining his opinion that
Petitioner did not have GBS, he opined that the onset of symptoms “that could potentially be
related to GBS” was December 24-25, 2013, approximately 48 days after vaccination. Id. at 144.
Dr. Vartanian opined that 48 days after vaccination is not an appropriate timeframe to support
causation. Id. He remarked that vaccination is “a potent immune stimulus” and that the ensuing
immune response is “fairly predictable in terms of the temporal course of antibody response. Id.
at 144-45. He added that “most vaccines induce a relatively robust humeral response in two
weeks,” meaning that symptom onset should occur two to three weeks after vaccination. Id. at 145.
He opined that the timing of onset of Petitioner’s condition does not fit either GBS or fibromyalgia.
Id. at 146.
Dr. Vartanian opined that the record as to Petitioner’s facial diplegia was “perplexing” in
that not all of Petitioner’s providers made a note of it. Tr. at 148. He opined that he would not
expect facial diplegia associated with GBS to be “transient,” but in Petitioner’s case, “it wasn’t
substantiated on subsequent exams.” Id. He noted that demyelination severe enough to result in
facial diplegia can take weeks or months to repair. Id. at 160. He later opined that Dr. Pidgeon’s
examination of Petitioner had been less than thorough and that Dr. Pidgeon had failed to describe
Petitioner’s facial diplegia in sufficient detail. Id. at 157. Dr. Vartanian reiterated his opinion that
Petitioner did not have GBS, adding that if she did, he would suspect her prior infection, rather
than the flu vaccine, as being causative. Id. at 155.
Dr. Vartanian acknowledged that the possibility of GBS evolving into fibromyalgia as Dr.
Kinsbourne theorized is the subject of ongoing investigation. Tr. at 154 (“I’m not sure I would
regard it as definitive or textbook…I don’t really dispute it as a possibility.”). He also
acknowledged that there is medical literature documenting patients with GBS who experience
burning, pain, and paresthesias. Id.
Dr. Vartanian expressed uncertainty as to one aspect of Petitioner’s medical record. He
opined that the evidence of meningeal or leptomeningeal enhancement of Petitioner’s thoracic
spinal cord had gone without any further evaluation. Tr. at 159. He opined that this omission was
bothersome. Id.
Dr. Vartanian next explained how elevated protein in CSF can be an indicator of GBS. Tr.
at 163. He explained that normally, the protein content of CSF is very low. Id. at 164. In GBS
19

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 20 of 34
patients, there is frequently damage to the barrier between the bloodstream and the spinal cord,
causing protein, mainly albumin, to leak into and mix with CSF. Id. at 163-64. This can cause the
level of protein in CSF to become “quite high.” Id. at 164. He again noted that Petitioner’s CSF
protein was only minimally elevated, a finding that could be explained by the ruptured L4-L5 disc.
Id.
Dr. Vartanian also noted that Petitioner had taken cyclobenzaprine, a muscle relaxer, and
Savella, a selective serotonin reuptake inhibitor, as treatment for fibromyalgia, and had seen some
improvement. Tr. at 167.
IV. Affidavit and Fact Testimony: Melissa Larson
A. Petitioner’s Affidavit
Petitioner filed her affidavit on April 27, 2017. Ex. 14 (“Pet. Aff.”). In it, Petitioner averred
that she received the allegedly causal flu vaccine on November 6, 2013. Id. at 2. She stated that,
on December 4, 2013, she “left work early because [she] was feeling hot, weak, and [she] was
sweating.” Id. She described the onset of back pain that was “not extremely painful” in the evening
on December 16, 2013, and waking the next morning with more severe pain such that she reported
to the emergency room later that day. Id. She stated that playing with her child in the evening of
December 16 seemed to exacerbate her back pain. Id.
Petitioner next described the progression of her pain and other symptoms over the
following days. Pet. Aff. at 3. She stated that she saw Dr. Bhushan on December 20 and was
prescribed Percocet, prednisone, a muscle relaxer, and an anti-inflammatory. Id. She described
worsening pain and weakness on December 20, and experienced trouble walking. Id. Petitioner
averred that she developed worsening pain such that she was unable to get out of bed from
December 20 to 23, and that the medication did not help. Id. She returned to Dr. Bhushan on
December 24 due to her worsening pain. Id. Dr. Bhushan referred her to a neurologist. Id.
Petitioner stated that on December 25, 2013, she began to have difficulty breathing while
trying to sleep. Pet. Aff. at 3. This feeling continued through the night and did not improve when
she changed position. Id. Petitioner’s pain continued the following day and she continued to feel
hot and to have trouble breathing. Id. Petitioner stated that she saw a neurologist on December 27.
Id. Her legs felt heavy and she had trouble standing, walking, moving her arms, and speaking. Id.
She was sent to St. Luke’s Hospital in Milwaukee. Id.
B. Petitioner’s Testimony
Petitioner testified at the entitlement hearing on November 8, 2021. Petitioner was 36 years
old and working as a respiratory therapist when she received the flu vaccine on November 6, 2013.
Tr. at 8. Flu vaccination was a condition of her employment at Aurora Healthcare, and she received
the vaccine at work. Id.
Petitioner testified that she first began experiencing problems on the evening of December
16, 2013. Tr. at 8. After a day and night of rest, Petitioner’s pain had worsened and she reported
20

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 21 of 34
to the emergency room. Id. at 9. Petitioner’s regular physician prescribed muscle relaxers and
steroids, but the pain continued and was severe enough that Petitioner was unable to get into the
shower unassisted. Id. at 9-10.
Between December 16 and 23, 2013, Petitioner felt her condition worsen. Tr. at 11. She
described the muscle weakness she experienced, analogizing it to the sensation of having cinder
blocks attached to each of her feet and of having foam mattress pads wrapped around each of her
limbs. Id. She would also wake with a gasp in the middle of the night. Id. at 11-12.
In December 2013, Petitioner saw her regular physician, who ordered an MRI. Tr. at 12.
The MRI revealed a bulging disc between L4 and L5. Id. She saw Dr. Pidgeon, a neurologist, on
December 27, 2013. Id. Petitioner required assistance from her teenage son to get into the car and
she felt like a person was sitting on her chest during the ride to Dr. Pidgeon’s office. Id. 12-13.
She described the sensation of her face drooping as feeling as though her face was made of wax.
Id. at 13. Dr. Pidgeon recommended that she be transferred to the emergency room, which she was
that same day. Id. at 14. She testified that her speech was slurred and described feeling like her
body was made of Jell-O. Id. at 14-15. She also described feeling alternately hot and cold. Id. at
15.
Petitioner testified that prior to the onset of her condition, she was in perfect health and
was able to work a 12-hour shift as a respiratory therapist with only minimal breaks. Tr. at 16.
Roughly one month after her initial hospital admission, Petitioner began experiencing prickling or
burning pain in the backs of her legs. Id. at 18. This prevented her from sitting or kneeling
comfortably and lasted about one year. Id. During this time, heaviness in her arms also prevented
her from being able to lift anything or fold laundry. Id. at 19.
Petitioner testified that she began to feel better around December 28, 2013. Tr. at 19.
However, she had to take frequent rest breaks from whatever she was doing. Id. at 20. She was
discharged from the hospital on December 31 because her condition plateaued, and her providers
were no longer concerned about respiratory failure. Id. at 21. She was never put on a ventilator.
Id.
In March 2014, Petitioner was readmitted to the hospital when her condition suddenly
worsened after she attempted to clean her bathroom. Tr. at 21. She had pain in the backs of her
legs, heaviness and weakness in her limbs, and drooping in her face. Id. at 22. The pain in her legs
persisted until December 2015, when her condition generally began to improve. Id. at 23.
Petitioner returned to work as a respiratory therapist in April 2016. Id.
Petitioner testified that, shortly after she received the flu vaccine in early November 2013,
she and her family all came down with a stomach virus that lasted three to four days. Tr. at 24.
Petitioner never had a fever during this time. Id. at 25.
During cross-examination, Petitioner confirmed that, on December 18, 2013, her only
symptom was back pain. Tr. at 25. Petitioner disagreed with the medical record of her December
24, 2013, visit to her regular physician which states that Petitioner denied weakness, tiredness, and
malaise at that visit. Id. at 25-26. She testified that she had the feeling of cinder blocks on her limbs
21

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 22 of 34
and “could not move” at that time. Id. at 26. Petitioner confirmed that she began feeling weak and
numb all over approximately two to three days before she saw Dr. Pidgeon on December 27. Id.
at 27. Petitioner confirmed that she never received IVIG or plasmapheresis. Id. at 28.
Petitioner testified that, while it is true that Drs. Cueva, Marriott, Lotz, and Dotson believed
that she did not have GBS, none of these providers saw her during the “acute stage” of her illness.
Id. at 29-30.
Petitioner testified that she was diagnosed with fibromyalgia in October 2014. Tr. at 30.
Petitioner received treatment for fibromyalgia for two years, but testified that she was reluctant to
take the medications she was prescribed because she did not want to be tired. Id. at 32.
V. Applicable Law
A. Petitioner’s Burden
Under the Vaccine Act, a petitioner may prevail in one of two ways. First, a petitioner may
demonstrate that she suffered a “Table” injury—i.e., an injury listed on the Vaccine Injury Table
that occurred within the time period provided in the Table. § 11(c)(1)(C)(i). “In such a case,
causation is presumed.” Capizzano v. Sec’y of Health & Hum. Servs., 440 F.3d 1317, 1320 (Fed.
Cir. 2006); see § 13(a)(1)(B). Second, where the alleged injury is not listed in the Vaccine Injury
Table, a petitioner may demonstrate that she suffered an “off-Table” injury. § 11(c)(1)(C)(ii).
For both Table and non-Table claims, Vaccine Program petitioners bear a “preponderance
of the evidence” burden of proof. Section 13(1)(a). That is, a petitioner must offer evidence that
leads the “trier of fact to believe that the existence of a fact is more probable than its nonexistence
before [he] may find in favor of the party who has the burden to persuade the judge of the fact’s
existence.” Moberly v. Sec’y of Health & Hum. Servs., 592 F.3d 1315, 1324 (Fed. Cir. 2010); see
also Snowbank Enter. v. United States, 6 Cl. Ct. 476, 486 (1984) (mere conjecture or speculation
is insufficient under a preponderance standard). Proof of medical certainty is not required. Bunting
v. Sec’y of Health & Hum. Servs., 931 F.2d 867, 873 (Fed. Cir. 1991). In particular, a petitioner
must demonstrate that the vaccine was “not only [the] but-for cause of the injury but also a
substantial factor in bringing about the injury.” Moberly, 592 F.3d at 1321 (quoting Shyface v.
Sec’y of Health & Hum. Servs., 165 F.3d 1344, 1352 (Fed. Cir. 1999)); Pafford v. Sec’y of Health
& Hum. Servs., 451 F.3d 1352, 1355 (Fed. Cir. 2006). A petitioner may not receive a Vaccine
Program award based solely on his assertions; rather, the petition must be supported by either
medical records of by the opinion of a competent physician. Section 13(a)(1).
In attempting to establish entitlement to a Vaccine Program award of compensation for a
non-Table claim, a petitioner must satisfy all three of the elements established by the Federal
Circuit in Althen. Althen requires that petitioner establish by preponderant evidence that the
vaccinations he received caused her injury “by providing: (1) a medical theory causally connecting
the vaccination and the injury; (2) a logical sequence of cause and effect showing that the
22

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 23 of 34
vaccination was the reason for the injury; and (3) a showing of a proximate temporal relationship
between vaccination and injury.” Id. at 1278.
Each of the Althen prongs requires a different showing. Under Althen prong one, petitioners
must provide a “reputable medical theory,” demonstrating that the vaccine received can cause the
type of injury alleged. Pafford, 451 F.3d at 1355-56 (citations omitted). To satisfy this prong, a
petitioner’s theory must be based on a “sound and reliable medical or scientific explanation.”
Knudsen v. Sec’y of Health & Hum. Servs., 35 F.3d 543, 548 (Fed. Cir. 1994). Such a theory must
only be “legally probable, not medically or scientifically certain.” Id. at 549.
Petitioners may satisfy the first Althen prong without resort to medical literature,
epidemiological studies, demonstration of a specific mechanism, or a generally accepted medical
theory. Andreu v. Sec’y of Health & Hum. Servs., 569 F.3d 1367, 1378-79 (Fed. Cir. 2009) (citing
Capizzano, 440 F.3d at 1325-26). Special Masters, despite their expertise, are not empowered by
statute to conclusively resolve what are complex scientific and medical questions, and thus
scientific evidence offered to establish Althen prong one is viewed “not through the lens of the
laboratorian, but instead from the vantage point of the Vaccine Act’s preponderant evidence
standard.” Id. at 1380. Accordingly, special masters must take care not to increase the burden
placed on petitioners in offering a scientific theory linking vaccine to injury. Contreras v. Sec’y of
Health & Hum. Servs., 121 Fed. Cl. 230, 245 (2015) (“[p]lausibility … in many cases may be
enough to satisfy Althen prong one” (emphasis in original)), vacated on other grounds, 844 F.3d
1363 (Fed. Cir. 2017). But this does not negate or reduce a petitioner’s ultimate burden to establish
her overall entitlement to damages by preponderant evidence. W.C. v. Sec’y of Health & Hum.
Servs., 704 F.3d 1352, 1356 (Fed. Cir. 2013) (citations omitted).
The second Althen prong requires proof of a logical sequence of cause and effect, usually
supported by facts derived from a petitioner’s medical records. Althen, 418 F.3d at 1278; Andreu,
569 F.3d at 1375-77; Capizzano, 440 F.3d at 1326 (“medical records and medical opinion
testimony are favored in vaccine cases, as treating physicians are likely to be in the best position
to determine whether a ‘logical sequence of cause and effect show[s] that the vaccination was the
reason for the injury’”) (quoting Althen, 418 F.3d at 1280). Medical records are generally viewed
as particularly trustworthy evidence, because they are created contemporaneously with the
treatment of the patient. Cucuras v. Sec’y of Health & Hum. Servs., 993 F.2d 1525, 1528 (Fed. Cir.
1993).
However, medical records and/or statements of a treating physician’s views do not per se
bind the special master to adopt the conclusions of such an individual, even if they must be
considered and carefully evaluated. Section 13(b)(1) (providing that “[a]ny such diagnosis,
conclusion, judgment, test result, report, or summary shall not be binding on the special master or
court”); Snyder v. Sec’y of Health & Hum. Servs., 88 Fed. Cl. 706, 746 n.67 (2009) (“there is
nothing … that mandates that the testimony of a treating physician is sacrosanct -- that it must be
accepted in its entirety and cannot be rebutted”). As with expert testimony offered to establish a
theory of causation, the opinions or diagnoses of treating physicians are only as trustworthy as the
reasonableness of their suppositions or bases. The views of treating physicians should also be
weighed against other, contrary evidence also present in the record -- including conflicting
opinions among such individuals. Hibbard v. Sec’y of Health & Hum. Servs., 100 Fed. Cl. 742,
23

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 24 of 34
749 (2011) (not arbitrary or capricious for special master to weigh competing treating physicians’
conclusions against each other), aff’d, 698 F.3d 1355 (Fed. Cir. 2012); Caves v. Sec’y of Health &
Hum. Servs., No. 06-522V 2011 WL 1935813 at *17 (Fed. Cl. Spec. Mstr. Apr. 29, 2011), mot.
for review den’d, 100 Fed. Cl. 344, 356 (2011), aff’d without opinion, 475 Fed. App’x 765 (Fed.
Cir. 2012).
The third Althen prong requires establishing a “proximate temporal relationship” between
the vaccination and the injury alleged. Althen, 418 F.3d at 1281. That term has been equated to the
phrase “medically-acceptable temporal relationship.” Id. A petitioner must offer “preponderant
proof that the onset of symptoms occurred within a timeframe which, given the medical
understanding of the disorder’s etiology, it is medically acceptable to infer causation.” de Bazan
v. Sec’y of Health & Hum. Servs., 539 F.3d 1347, 1352 (Fed. Cir. 2008). The explanation for what
is a medically acceptable timeframe must also coincide with the theory of how the relevant vaccine
can cause an injury (Althen prong one’s requirement). Id. at 1352; Shapiro v. Sec’y of Health &
Hum. Servs., 101 Fed. Cl. 532, 542 (2011), recons. denied after remand on other grounds, 105
Fed. Cl. 353 (2012), aff’d without op., 503 F. App’x 952 (Fed. Cir. 2013). Koehn v. Sec’y of Health
& Hum. Servs., No. 11-355V, 2013 WL 3214877 (Fed. Cl. Spec. Mstr. May 30, 2013), mot. for
review den’d (Fed. Cl. Dec. 3, 2013), aff’d, 773 F.3d 1239 (Fed. Cir. 2014).
B. Law Governing Analysis of Fact Evidence
The process for making factual determinations in Vaccine Program cases begins with
analyzing the medical records, which are required to be filed with the petition. Section 11(c)(2).
The special master is required to consider “all [] relevant medical and scientific evidence contained
in the record,” including “any diagnosis, conclusion, medical judgment, or autopsy or coroner’s
report which is contained in the record regarding the nature, causation, and aggravation of the
petitioner’s illness, disability, injury, condition, or death,” as well as the “results of any diagnostic
or evaluative test which are contained in the record and the summaries and conclusions.” Section
13(b)(1)(A). The special master is then required to weigh the evidence presented, including
contemporaneous medical records and testimony. See Burns v. Sec’y of Health & Hum. Servs., 3
F.3d 413, 417 (Fed. Cir. 1993) (it is within the special master’s discretion to determine whether to
afford greater weight to contemporaneous medical records than to other evidence, such as oral
testimony surrounding the events in question that was given at a later date, provided that such
determination is evidenced by a rational determination).
Medical records created contemporaneously with the events they describe are generally
trustworthy because they “contain information supplied to or by health professionals to facilitate
diagnosis and treatment of medical conditions,” where “accuracy has an extra premium.” Kirby v.
Sec’y of Health & Hum. Servs., 997 F.3d 1378 (Fed. Cir. 2021) citing Cucuras, 993 F.2d at 1528.
This presumption is based on the linked proposition that (i) sick people visit medical professionals;
(ii) sick people honestly report their health problems to those professionals; and (iii) medical
professionals record what they are told or observe when examining their patients in as accurate a
manner as possible, so that they are aware of enough relevant facts to make appropriate treatment
decisions. Sanchez v. Sec’y of Health & Hum. Servs., No. 11-685V, 2013 WL 1880825 at *2 (Fed.
Cl. Spec. Mstr. Apr. 10, 2013) mot. for rev. denied, 142 Fed. Cl. 247, 251-52 (2019), vacated on
other grounds and remanded, 809 Fed. Appx. 843 (Fed. Cir. Apr. 7, 2020).
24

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 25 of 34
Accordingly, if the medical records are clear, consistent, and complete, then they should
be afforded substantial weight. Lowrie v. Sec’y of Health & Hum. Servs., No. 03-1585V, 2005 WL
6117475 at *20 (Fed. Cl. Spec. Mstr. Dec. 12, 2005). Indeed, contemporaneous medical records
are generally found to be deserving of greater evidentiary weight than oral testimony -- especially
where such testimony conflicts with the record evidence. Cucuras, 993 F.2d at 1528; see also
Murphy v. Sec’y of Health & Hum. Servs., 23 Cl. Ct. 726, 733 (1991), aff’d per curiam, 968 F.2d
1226 (Fed. Cir. 1992), cert. den’d, Murphy v. Sullivan, 506 U.S. 974 (1992) (citing United States
v. U.S. Gypsum Co., 333 U.S. 364, 396 (1947) (“[i]t has generally been held that oral testimony
which is in conflict with contemporaneous documents is entitled to little evidentiary weight.”)).
However, there are situations in which compelling oral testimony may be more persuasive
than written records, such as where records are deemed to be incomplete or inaccurate. Campbell
v. Sec’y of Health & Hum. Servs., 69 Fed. Cl. 775, 779 (2006) (“like any norm based upon common
sense and experience, this rule should not be treated as an absolute and must yield where the factual
predicates for its application are weak or lacking”); Lowrie, 2005 WL 6117475 at *19 (“[w]ritten
records which are, themselves, inconsistent, should be accorded less deference than those which
are internally consistent”) (quoting Murphy, 23 Cl. Ct. at 733)). Ultimately, a determination
regarding a witness’s credibility is needed when determining the weight that such testimony should
be afforded. Andreu, 569 F.3d at 1379; Bradley v. Sec’y of Health & Hum. Servs., 991 F.2d 1570,
1575 (Fed. Cir. 1993).
When witness testimony is offered to overcome the presumption of accuracy afforded to
contemporaneous medical records, such testimony must be “consistent, clear, cogent and
compelling.” Sanchez, 2013 WL 1880825 at *3 (citing Blutstein v. Sec’y of Health & Hum. Servs.,
No. 90-2808V, 1998 WL 408611 at *5 (Fed. Cl. Spec. Mstr. June 30, 1998)). In determining the
accuracy and completeness of medical records, the Court of Federal Claims has listed four possible
explanations for inconsistencies between contemporaneously created medical records and later
testimony: (1) a person’s failure to recount to the medical professional everything that happened
during the relevant time period; (2) the medical professional’s failure to document everything
reported to her or him; (3) a person’s faulty recollection of the events when presenting testimony;
or (4) a person’s purposeful recounting of symptoms that did not exist. LaLonde v. Sec’y of Health
& Hum. Servs., 110 Fed. Cl. 184, 203-04 (2013), aff’d, 746 F.3d 1334 (Fed. Cir. 2014). In making
a determination regarding whether to afford greater weight to contemporaneous medical records
or other evidence, such as testimony at hearing, there must be evidence that this decision was the
result of a rational determination. Burns, 3 F.3d at 417.
C. Analysis of Expert Testimony
Establishing a sound and reliable medical theory connecting the vaccine to the injury often
requires a petitioner to present expert testimony in support of his or her claim. Lampe v. Sec’y of
Health & Hum. Servs., 219 F.3d 1357, 1361 (Fed. Cir. 2000). Vaccine Program expert testimony
is usually evaluated according to the factors for analyzing scientific reliability set forth in Daubert
v. Merrell Dow Pharm., Inc., 509 U.S. 579, 594-96 (1993). See Cedillo v. Sec’y of Health & Hum.
Servs., 617 F.3d 1328, 1339 (Fed. Cir. 2010) (citing Terran v. Sec’y of Health & Hum. Servs., 195
F.3d 1302, 1316 (Fed. Cir. 1999). “The Daubert factors for analyzing the reliability of testimony
25

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 26 of 34
are: (1) whether a theory or technique can be (and has been) tested; (2) whether the theory or
technique has been subjected to peer review and publication; (3) whether there is a known or
potential rate of error and whether there are standards for controlling the error; and (4) whether the
theory or technique enjoys general acceptance within a relevant scientific community.” Terran,
195 F.3d at 1316 n.2 (citing Daubert, 509 U.S. at 592-95).
The Daubert factors play a slightly different role in Vaccine Program cases than they do
when applied in other federal judicial fora. Daubert factors are employed by judges to exclude
evidence that is unreliable and potentially confusing to a jury. In Vaccine Program cases, these
factors are used in the weighing of the reliability of scientific evidence. Davis v. Sec’y of Health
& Hum. Servs., 94 Fed. Cl. 53, 66-67 (2010) (“uniquely in this Circuit, the Daubert factors have
been employed also as an acceptable evidentiary-gauging tool with respect to persuasiveness of
expert testimony already admitted”). The flexible use of the Daubert factors to evaluate
persuasiveness and reliability of expert testimony has routinely been upheld. See, e.g., Snyder, 88
Fed. Cl. at 743. In this matter, (as in numerous other Vaccine Program cases), Daubert has not
been employed at the threshold, to determine what evidence should be admitted, but instead to
determine whether expert testimony offered is reliable and/or persuasive.
Respondent frequently offers one or more experts of his own in order to rebut a petitioner’s
case. Where both sides offer expert testimony, a special master’s decision may be “based on the
credibility of the experts and the relative persuasiveness of their competing theories.”
Broekelschen v. Sec’y of Health & Hum. Servs., 618 F.3d 1339, 1347 (Fed. Cir. 2010) (citing
Lampe, 219 F.3d at 1362). However, nothing requires the acceptance of an expert’s conclusion
“connected to existing data only by the ipse dixit of the expert,” especially if “there is simply too
great an analytical gap between the data and the opinion proffered.” Snyder, 88 Fed. Cl. at 743
(quoting Gen. Elec. Co. v. Joiner, 522 U.S. 136, 146 (1997)). A “special master is entitled to
require some indicia of reliability to support the assertion of the expert witness.” Moberly, 592
F.3d at 1324. Weighing the relative persuasiveness of competing expert testimony, based on a
particular expert’s credibility, is part of the overall reliability analysis to which special masters
must subject expert testimony in Vaccine Program cases. Id. at 1325-26 (“[a]ssessments as to the
reliability of expert testimony often turn on credibility determinations”); see also Porter v. Sec’y
of Health & Hum. Servs., 663 F.3d 1242, 1250 (Fed. Cir. 2011) (“this court has unambiguously
explained that special masters are expected to consider the credibility of expert witnesses in
evaluating petitions for compensation under the Vaccine Act”).
D. Consideration of Medical Literature
Finally, although this decision discusses some but not all of the medical literature in detail,
I have reviewed and considered all of the medical records and literature submitted in this matter.
See Moriarty v. Sec’y of Health & Hum. Servs., 844 F.3d 1322, 1328 (Fed. Cir. 2016) (“We
generally presume that a special master considered the relevant record evidence even though [s]he
does not explicitly reference such evidence in h[er] decision.”); Simanski v. Sec’y of Health &
Hum. Servs., 115 Fed. Cl. 407, 436 (2014) (“[A] Special Master is ‘not required to discuss every
piece of evidence or testimony in her decision.’” (citation omitted)), aff’d, 601 F. App’x 982 (Fed.
Cir. 2015).
26

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 27 of 34
VI. Analysis
Petitioner alleges that the flu vaccination she received on November 6, 2013, caused her to
develop GBS. Petitioner argues that she is entitled to compensation based on a causation-in-fact
analysis as opposed to a Table claim.10 Pet. at 1; Pet’r’s Pre-Hearing Brief at 2; Pet’r’s Post-
Hearing Brief at 2.
As a threshold matter, a petitioner must establish that she suffers from the condition for
which she seeks compensation. Broekelschen v. Sec’y of Health & Hum. Servs., 618 F.3d 1339,
1346 (Fed. Cir. 2010). “The function of a special master is not to ‘diagnose’ vaccine-related
injuries, but instead to determine ‘based on the record as a whole and the totality of the case,
whether it has been shown by a preponderance of the evidence that a vaccine caused the
[petitioner]’s injury.’” Andreu v. Sec’y of Health & Hum. Servs., 569 F.3d 1367, 1382 (Fed. Cir.
2009) (quoting Knudsen v. Sec’y of Health & Hum. Servs., 35 F.3d 543, 549 (Fed. Cir. 1994)).
“Although the Vaccine Act does not require absolute precision, it does require the petitioner to
establish an injury -- the Act specifically creates a claim for compensation for ‘vaccine-related
injury or death.’” Stillwell v. Sec'y of Health & Hum. Servs., 118 Fed. Cl. 47, 56 (2014) (quoting
42.U.S.C. § 300aa-11(c)). Accordingly, the Federal Circuit has established that it is “appropriate
for the special master to first determine what injury, if any, [is] supported by the evidence presented
in the record” before applying a causation analysis pursuant to Althen v. Secretary of Health &
Hum. Services, 418 F.3d 1274 (Fed. Cir. 2005). Lombardi v. Sec’y of Health & Hum. Servs., 656
F.3d 1343, 1351-53 (Fed. Cir. 2011). In this case, Petitioner has not demonstrated that she suffered
from GBS.
A. Petitioner has not Established that GBS is her Correct Diagnosis
When determining whether a petitioner has adequately proven a demonstrable injury,
special masters analyze the petitioner’s complete medical records filed into the record. 42 U.S.C.
§ 300aa-11(c)(2). Medical records created contemporaneously with the events they describe are
presumed to be accurate and complete such that they present all relevant information on a
petitioner’s health problems. Cucuras v. Sec'y of Health & Hum. Servs., 993 F.2d 1525, 1528 (Fed.
Cir. 1993).
As an initial matter, Petitioner’s experts did not agree on her diagnosis. Dr. Karussis and
Dr. Kinsbourne opined that Petitioner developed GBS in December 2013 and that her symptoms
10 GBS was added to the Vaccine Injury Table in March of 2017. However, the Vaccine Act specifies that
the version of the Table that exists at the time a petition is filed is the version of the Table that controls. 42
U.S.C. § 300aa-14(c)(4). Because this case was filed in 2016, there is no Table injury of GBS relative to
this petition. Theoretically, Petitioner could have refiled this case on or after March 21, 2017, to take
advantage of the addition of GBS to the Table. However, this was not done. In any event, even if Petitioner
had refiled such that a Table Injury could be considered, this fact would not change my weighing of the
evidence and my finding that Petitioner has not preponderantly demonstrated that she suffered GBS. For
example, the QAI for GBS specifies that a petitioner must demonstrate their condition to have been
monophasic in order to establish GBS as a Table Injury, and I conclude in section (VI)(A)(1) infra that this
Petitioner’s clinical presentation was not monophasic. 42 C.F.R. § 100.3.
27

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 28 of 34
in March 2014 were also attributable to GBS. They specifically testified that she did not have
fibromyalgia. See Karussis Rep. at 5 (stating “it is not clear why fibromyalgia has been proposed
to substitute the Guillain Barre syndrome diagnosis.”); Tr. at 47 (Dr. Kinsbourne testifying that
“there was no affirmative evidence for fibromyalgia that I could see in the record.”). Dr. Shoenfeld
stated that Petitioner’s GBS in December 2013 progressed to fibromyalgia by a parallel
autoimmune reaction to the flu vaccine. Tr. at 91. At the end of the hearing, I asked Petitioner’s
counsel to state what injury Petitioner was alleging. Counsel responded as follows:
MR. MCHUGH: She’s alleging Guillain-Barre syndrome and the aftermath of the
two years of this burning sensation and the lack of energy that kept her from
working. I guess it’s actually two and a half years.
THE COURT: Is she alleging fibromyalgia?
MR. MCHUGH: No, she’s alleging Guillain-Barre syndrome. Now, we
understand--
THE COURT: I understand that.
MR. MCHUGH: Yeah. The symptoms -- we believe the symptoms of one become
the other. So, yes, there are two schools of thought that fibromyalgia can follow it,
or be part of it, but it’s -- the literature seems to indicate that this kind of sequelae
is seen in Guillain-Barre. So it really doesn’t matter whether it’s Guillain-Barre
syndrome or fibromyalgia, it started with the vaccination and the initial attack of
Guillain-Barre, which then may have converted to something else. …
Tr. at 177 (emphasis added). Because I have determined that Petitioner did not have GBS, I have
not analyzed whether she developed fibromyalgia after and as a consequence of GBS.
According to Respondent’s expert, Dr. Vartanian, a GBS diagnosis based on “clinical
presentation, EMG/NCS findings, and CSF analysis.” Vartanian Rep. at 11. Petitioner’s expert,
Dr. Kinsbourne, agreed. Tr. at 68. I now examine each of these in turn, as well as the opinions of
Petitioner’s treating physicians.
1. Clinical Presentation
First, Dr. Vartanian opined that Petitioner’s medical records show that her initial GBS
diagnosis was never confirmed. Tr. at 125. Dr. Vartanian noted in his expert report and during
testimony that Petitioner’s case is not typical of GBS, emphasizing in particular that Petitioner
never lost her reflexes. Vartanian Rep. at 12; Tr. at 125. Petitioner’s medical literature supports
this contention. Fokke, et al., Diagnosis of Guillain-Barré syndrome and validation of Brighton
criteria, 137 BRAIN 33-43 (2014) (filed as Ex. 17) (“Fokke”) (noting that all of the study’s 395
GBS patients developed hyporeflexia in the legs); Dimachkie & Barohn, Guillain-Barré Syndrome
and Variants, 31(2) NEUROL. CLINICS 491-510 (2013) (filed as Ex. 22) (“Dimachkie & Barohn”)
(clinical features of GBS include hyporeflexia or areflexia “within the first few days, but this may
be delayed by up to a week.”). Petitioner presented evidence that some GBS patients do not lose
28

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 29 of 34
reflexes. Yuki found that 10% of patients in their study’s cohort retained reflexes or exhibited
exaggerated reflexes throughout their disease course. Yuki at 1181. Fokke noted that two patients
in their cohort “had initial hyperreflexia in weak limbs,” one of whom was areflexic the next day.
Fokke at 37. I conclude that it is possible, though rare, for a patient to have GBS but not lose
reflexes. The fact that Petitioner had exaggerated reflexes suggests that GBS is not her correct
diagnosis.
Second, the medical literature characterizes GBS as a monophasic disorder.11 Fokke at 40;
Goodfellow & Willison, Guillain-Barré syndrome: a century of progress, 12 NATURE REVS.:
NEUROL. 723-31, 724 (2016) (filed as Ex. 18) (“Goodfellow & Willison”). GBS is known to recur
in a small minority of patients (2-5%) for reasons as yet unknown. Kuitwaard, et al., Recurrent
Guillain-Barré syndrome, 80 J. NEUROL, NEUROSURGERY, & PSYCHIATRY 56-59, 56 (2009) (filed
as Ex. 21) (“Kuitwaard”). Petitioner’s condition was improving in early 2014 and then deteriorated
again suddenly in March of that year when Petitioner had to be hospitalized for a second time. Tr.
at 19-21. This, by definition, is not a monophasic disorder. The course of Petitioner’s disease is
inconsistent with GBS because Petitioner experienced two distinct episodes of clinical worsening.
Third, the experts disagree as to the significance of Petitioner’s facial diplegia. Dr.
Kinsbourne opined that facial diplegia is “uniquely found in [GBS] in this particular context” and
that he knew of no alternative diagnosis that would explain the rapid onset of facial diplegia that
Petitioner experienced. Tr. at 41. He also opined that facial diplegia is inconsistent with
fibromyalgia. Id. at 74. Dr. Vartanian countered that Petitioner’s facial diplegia was never
completely described and that it appeared to come and go. Tr. at 148. This position is supported
by Petitioner’s medical records. (Compare Ex. 4 at 5, Petitioner’s December 27, 2013 visit with
Dr. Pidgeon where he noted facial diplegia with Ex. 5a at 77, an ER visit that same day where Dr.
Ravichandran documented no facial weakness and “no plegia”). Dr. Vartanian opined that in a
case of GBS, he would not expect facial diplegia to be “transient” in this way. Id. Dr. Vartanian’s
opinion is persuasive; furthermore, Petitioner did not provide evidence to rebut Dr. Vartanian’s
opinion on this issue.
Finally, I note that Petitioner’s condition improved after each hospitalization without resort
to plasmapheresis or IVIG, the two primary treatments for GBS. Tr. at 60, 70; Goodfellow &
Willison at 727-28. Dr. Vartanian opined that, while spontaneous remission does occur in some
cases, GBS is in general a progressive disorder that “tends to persist or progress in the absence of
treatment.” Tr. at 128-29. Fokke reported a mere 4% of the GBS patients in their cohort recovered
without treatment. Fokke at 36. It is compelling, too, that Petitioner did undergo treatment for
fibromyalgia, which caused her condition to improve. Tr. at 167.
Taking these four pieces of evidence together, I conclude that Petitioner’s clinical
presentation was not consistent with GBS.
2. CSF Analysis
Petitioner underwent a lumbar puncture on December 27, 2013, roughly ten days after the
11 Monophasic means “having one phase or variation.” DORLAND’S, https://www.dorlandsonline
.com/dorland/definition?id=32043 (last visited Apr. 17, 2023).
29

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 30 of 34
onset of her back pain, and again on March 14, 2014, upon her readmission to the hospital. Ex. 5c
at 24; Ex. 5e at 5. At both times, the concentration of protein in her CSF was slightly elevated (57
and 49 respectively). Id. Further CSF studies after March 14, 2014, were normal. Ex. 5e at 20. Dr.
Kinsbourne opined that CSF is typically normal during the first week after GBS onset and rises in
the second week. Id. at 68. Petitioner’s medical literature supports this contention. Fokke at 6
(finding that patients were more likely to show elevated CSF protein as time progressed after
symptom onset). He further opined that Petitioner’s first CSF analysis showed elevated protein
consistent with what he would expect early in the course of GBS. Tr. at 56. Dr. Vartanian agreed
that CSF protein tends to rise in the second week after onset, but opined that it was significant that
Petitioner’s CSF protein was only slightly elevated even as the symptoms she was experiencing
were severe. Id. at 127. Dr. Karussis described that Petitioner’s CSF studies returned “negative
findings.” Karussis Rep. at 9.
Dr. Vartanian also compellingly explained that the annular tear in Petitioner’s L4-L5 disc
and the meningeal enhancement on her MRI could explain the slight elevation in her CSF protein.
Tr. at 127. On March 14, 2014, Dr. Cueva also noted that the bulging disc issue may have caused
Petitioner’s CSF protein concentration to rise slightly. Ex. 5e at 20. Dr. Vartanian agreed with
Petitioner’s treating physicians that the protein level in her CSF was not sufficiently high to support
a diagnosis of GBS. Tr. at 127.
I conclude that the increase in Petitioner’s CSF protein is reasonably explained by her
annular tear at L4-L5.
3. Nerve Conduction Study
Petitioner underwent nerve conduction testing on March 18, 2014, during her second
hospital admission. Ex. 5e at 33. Dr. Marriott noted that the results were normal and that the
etiology of Petitioner’s symptoms was still unknown. Id. Dr. Kinsbourne stated that the fact that
Petitioner’s EMG was normal does not change his opinion that Petitioner had GBS. Tr. at 69. He
opined that, because Petitioner had a mild case of GBS that resolved without IVIG or
plasmapheresis, he did not find it surprising that the EMG was not diagnostic. Id. Dr. Vartanian
disagreed, opining that, if GBS was the proper diagnosis, he would have expected abnormal EMG
results given the severity of the symptoms Petitioner reported at that time. Tr. at 128.
Petitioner’s own medical literature emphasizes the importance of EMG as a diagnostic tool
for GBS. Dimachkie & Barohn at 495 (“When GBS is suspected, electrophysiologic studies are
essential to confirm the diagnosis and exclude its mimics.”); Fokke at 38 (finding that only 1% of
GBS patients in the study’s cohort had normal EMG results).
I find that Petitioner’s EMG results are not consistent with a diagnosis of GBS.
4. Treating Physicians
When weighing evidence, special masters should consider the opinions of treating
physicians. Capizzano, 440 F.3d at 1326. The opinions of treating physicians about the appropriate
diagnosis are often persuasive because the physicians have direct experience with the patient
30

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 31 of 34
whom they are diagnosing. See McCulloch v. Sec’y of Health & Hum. Servs., No. 09-293V, 2015
WL 3640610, at *20 (Fed. Cl. Spec. Mstr. May 22, 2015).
Petitioner’s treating physicians considered a GBS diagnosis upon her initial presentation
in December 2013. See Ex. 4 at 5 (medical record from December 27, 2013 where Dr. Pidgeon
expressed his concern that Petitioner had GBS which could be a reaction to the flu shot); Ex. 5a at
81 (December 28, 2013 visit with Dr. Francisco Aguilar who noted that the “presumptive diagnosis
is possible Guillain-Barre.”); Ex. 5a at 94-95 (medical record from December 29, 2013, where Dr.
Ravichandran noted that Petitioner’s symptoms were clearly related to post-flu shot demyelinating
neuropathy); Ex. 5a at 69-70 (discharge paperwork from December 31, 2013, indicating that
Petitioner’s diagnosis was generalized weakness and “possible” GBS).
Later in time, however, Petitioner’s doctors began to disfavor a GBS diagnosis. On March
14, 2014, Dr. Cueva expressed doubt that Petitioner had GBS at that time and described her
examination as “pretty benign.” Ex. 5e at 4-5. During a visit on March 17, 2014, Dr. Marriott
opined that Petitioner’s condition was “[c]linically inconsistent with recurrent inflammatory
neuropathy.” Id. at 28. Dr. Bhushan believed Petitioner’s symptoms were more likely to be
somatoform in nature. Ex. 9 at 53. Dr. Lotz diagnosed Petitioner with “conversion reaction
simulating weakness in the left leg.” Ex. 11 at 4. He told Petitioner that she “does not have Guillain
Barre or Guillain Barre-like disease.” Id. In fact, Dr. Lotz told Petitioner “with certainty that she
does not have a serious underlying neurologic disease.” Id. In an examination on June 19, 2014,
Dr. Dotson described that several of Petitioner’s symptoms were “give way” and
“nonphysiologic”. She further opined on August 17, 2014, that Petitioner’s prior GBS diagnosis
was made “without objective evidence.” Ex. 6a at 67.
Further, it is significant to the issue of diagnosis that Petitioner’s treating physicians never
chose to treat her with IVIG or plasmapheresis. Ex. 5a at 10, 70. Dr. Vartanian opined at the
entitlement hearing that GBS is a progressive illness that “tends to persist or progress in the
absence of treatment.” Id. at 128. He added that, while cases of spontaneous remission have been
known, “no one would leave a bona fide case of GBS untreated in this modern era.” Id. at 128-29.
I find that the majority of Petitioner’s treating physicians did not believe that she had GBS.
Furthermore, the fact that none of her doctors administered typical medical treatment for this
condition further supports Respondent’s position that GBS is not Petitioner’s correct diagnosis.
The medical literature filed in this case indicates that GBS can be difficult to diagnose.
Fokke refers to GBS as a “spectrum of neuropathic disorders that may differ in the underlying
pathogenesis and clinical manifestations.” Fokke at 34. GBS has no pathognomonic clinical
characteristics, no known biomarkers, and a long list of conditions that may be clinically similar.
Id. Petitioner and Respondent provided evidence that clinical presentation, CSF analysis, and
EMG/NCS are the three indicators that support a diagnosis of GBS. Vartanian Rep. at 11; Tr. at
68. As shown above, Petitioner’s medical records do not support a diagnosis of GBS with respect
to any of these three domains. Dr. Vartanian testified that Petitioner’s providers were right to
suspect GBS at the time of symptom onset, but that later objective findings made it less likely. Tr.
at 149.
Ultimately, if GBS was Petitioner’s correct diagnosis, that would mean she is 1) among the
31

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 32 of 34
approximately 10% of patients who do not experience diminished reflexes (Yuki at 1181); 2)
among the 2-5% of patients who do not have a monophasic course (Kuitwaard at 56); 3) among
the 4% of GBS patients who recovered without treatment (Fokke at 36); and 4) among the
approximately 1% of patients with normal EMG results (Fokke at 38). While the co-occurrence of
all these clinical features is possible, I do not find it is more likely than not. Viewing the medical
record as a whole in light of the expert testimony and medical literature, I find that Petitioner has
not provided preponderant evidence that she had GBS.
Because Petitioner has not preponderantly established that she had GBS, further analysis
is unnecessary. However, for the sake of completeness, I will briefly analyze the Althen prongs.
B. Althen Prong One
In the Vaccine Program, “to establish causation, the standard of proof is preponderance of
evidence, not scientific certainty.” Langland v. Sec’y of Health & Hum. Servs., 109 Fed. Cl. 421,
441 (Fed Cir. 2013). Petitioner’s burden under Althen’s first prong is to provide a medical theory
causally connecting the vaccination and the injury. Id. This theory must be sound and reliable.
Boatmon, 941 F.3d at 1359. For the reasons discussed in detail below, I find that Petitioner has
provided a sound and reliable medical theory causally connecting the flu vaccine to GBS.
Petitioner correctly points out that the relationship between the flu vaccine and GBS is
sufficiently compelling that Respondent added it to the Vaccine Program Table in 2017, thus
triggering the presumption of causation in qualifying cases. “In placing GBS on the Vaccine Injury
Table relative to the flu vaccine, respondent had already recognized a causal relationship between
the flu vaccine and GBS under at least some circumstances.” Goforth v. Sec'y of Health & Hum.
Servs., No. 14-1128V, 2021 WL 6337672, at *33 (Fed. Cl. Spec. Mstr. Nov. 19, 2021) (citing
National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table, 82 Fed.
Reg. 6294-6301, 6295 (Jan. 19, 2017)).
Petitioner argues that she has satisfied prong one because “[t]he revised Table eliminates
any question that influenza vaccine can cause GBS.” Pet. Post-Hearing Br. at 10. As support for
her claim that the flu vaccine can cause GBS, Petitioner cited medical literature and provided both
expert reports and testimony from Dr. Shoenfeld. Dr. Shoenfeld’s theory that similarity between
peptide sequences in the flu vaccine and in nervous system proteins causes an autoimmune attack
on the peripheral nervous system (i.e., molecular mimicry) is well established in the Vaccine
Program. See, e.g., Conte v. Sec’y of Health & Hum. Servs., No. 17-403V, 2020 WL 5743696, at
*23 (Fed. Cl. Spec. Mstr. July 27, 2020); Barone v. Sec’y of Health & Hum. Servs., No. 11-707V,
2014 WL 6834557, at *8 (Fed. Cl. Spec. Mstr. Nov. 12, 2014); Stitt v. Sec’y of Health & Hum.
Servs., No. 09-653V, 2013 WL 3356791, at *8 (Fed. Cl. Spec. Mstr. May 31, 2013).
Accordingly, I find that Petitioner has provided a sound and reliable medical theory
causally linking the flu vaccine to GBS.
C. Althen Prong Two
Under Althen’s second prong, a petitioner must “prove a logical sequence of cause and
32

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 33 of 34
effect showing that the vaccination was the reason for the injury.” Althen, 418 F.3d at 1278. The
sequence of cause and effect must be “'logical' and legally probable, not medically or scientifically
certain.” Id. A petitioner is not required to show “epidemiologic studies, rechallenge, the presence
of pathological markers or genetic disposition, or general acceptance in the scientific or medical
communities to establish a logical sequence of cause and effect.” Id. (omitting internal citations).
Capizzano, 440 F.3d at 1325. Instead, circumstantial evidence and reliable medical opinions may
be sufficient to satisfy the second Althen prong.
Prong two requires Petitioner to preponderantly show that the flu vaccine actually did cause
her to develop GBS. While causation in flu vaccine/GBS cases is presumptive in certain instances,
this does not reduce a petitioner’s burden in an off-Table claim like this one. Grant v. Sec'y of
Health & Hum. Servs., 956 F.2d 1144, 1148 (Fed. Cir. 1992) (quoting H.R. Rep. No. 908, 99th
Cong., 2d Sess., pt. 1, at 15 (1986)). Congress was clear that “[s]imple similarity to conditions or
time periods listed in the Table is not sufficient evidence of causation.” Id.
As discussed above, I have found that Petitioner has not presented preponderant evidence
that she had GBS at all. Accordingly, Petitioner cannot show that the flu vaccine caused her to
develop GBS. Petitioner has not met her burden under Althen prong two.
D. Althen Prong Three
The timing prong contains two parts. First, a petitioner must establish the “timeframe for
which it is medically acceptable to infer causation” and second, she must demonstrate that the
onset of the disease occurred in this period. Shapiro v. Secʼy of Health & Hum. Servs., 101 Fed.
Cl. 532, 542-43 (2011), recons. denied after remand on other grounds, 105 Fed. Cl. 353 (2012),
aff’d without op., 503 F. App’x 952 (Fed. Cir. 2013).
There is no dispute that Petitioner received the flu vaccine on November 6, 2013. Ex. 2 at
2. Onset of the condition that Petitioner asserts is GBS is disputed, even among Petitioner’s
experts. Dr. Shoenfeld opined that Petitioner developed GBS “somewhere between December 6,
2013 – December 27, 2013,” or 30 to 51 days after vaccination. Shoenfeld Answers at 1. Dr.
Kinsbourne opined that Petitioner’s GBS began with the severe lower back pain she experienced
on December 16, 2013, 40 days after vaccination. Tr. at 40. On the other hand, Dr. Vartanian
opined that the sudden, acute low back pain Petitioner experienced on December 16, 2013, was in
fact not related to her condition, but instead to an annular tear. Id. at 119-20. Maintaining his
opinion that Petitioner did not actually have GBS, he opined that the onset of symptoms “that could
potentially be related to GBS” was December 24-25, 2013, approximately 48 days after
vaccination. Id. at 144.
Petitioner’s failure to show that she had GBS means (1) that the timeframe from which it
is medically acceptable to infer that the vaccine caused GBS is moot; and (2) that Petitioner cannot
show that she developed GBS within such a timeframe. Accordingly, Petitioner has not met her
burden under Althen prong three.
33

Case 1:16-vv-00633-AOB Document 113 Filed 06/01/23 Page 34 of 34
VI. Conclusion
Upon careful evaluation of all the evidence submitted in this matter, including the medical
records, the experts’ opinions and medical literature, I conclude that Petitioner has not shown by
preponderant evidence that she is entitled to compensation under the Vaccine Act. Her petition is
therefore DISMISSED. The clerk shall enter judgment accordingly.12
IT IS SO ORDERED.
s/ Katherine E. Oler
Katherine E. Oler
Special Master
12 Pursuant to Vaccine Rule 11(a), the parties may expedite entry of judgment by each filing (either jointly
or separately) a notice renouncing their right to seek review.
34

================================================================================
DOCUMENT 2: USCOURTS-cofc-1_16-vv-00633-2
Date issued/filed: 2023-10-02
Pages: 10
Docket text: REPORTED OPINION AND ORDER reissued 120 OPINION AND ORDER: Denying petitioner's 111 motion for review and the decision of the special master 110 is SUSTAINED. Signed by Judge Armando O. Bonilla. (ead) Service on parties made. Modified on 10/2/2023 - Corrected PDF. (jt1).
--------------------------------------------------------------------------------
Case 1:16-vv-00633-AOB Document 121 Filed 10/02/23 Page 1 of 10
In the United States Court of Federal Claims
FOR PUBLICATION
No. 16-633V
(Filed: October 2, 20231)
Corrected on October 2, 2023
)
MELISSA LARSON, )
)
Petitioner, )
)
v. )
)
SECRETARY OF HEALTH AND )
HUMAN SERVICES, )
)
Respondent. )
John F. McHugh, Law Office of John McHugh, New York, NY, for petitioner.
Alexa Roggenkamp, Trial Attorney, Torts Branch, Civil Division, U.S. Department of
Justice, Washington, DC, for respondent. With her on the briefs were Brian M.
Boynton, Principal Deputy Assistant Attorney General, and C. Salvatore D’Alessio,
Director, Heather L. Pearlman, Deputy Director, and Alexis B. Babcock, Assistant
Director, Torts Branch, Civil Division, U.S. Department of Justice, Washington, DC.
OPINION AND ORDER
BONILLA, Judge.
On May 27, 2016, Melissa Larson filed a petition for compensation under
the National Vaccine Injury Compensation Program, 42 U.S.C. § 300aa-10 et seq.,
initially claiming she developed fibromyalgia after receiving an influenza vaccine as a
condition of her employment as a healthcare worker. She subsequently claimed the
vaccine caused her to develop Guillain-Barré Syndrome (GBS), relegating
her asserted fibromyalgia diagnosis to the sequela of GBS. On April 28, 2023, the
1 This decision was initially filed under seal on September 15, 2023, in accordance with Rule 18(b)
of the Vaccine Rules of the United States Court of Federal Claims, to allow the parties to propose
redactions based upon privacy concerns. No proposed redactions were filed.

Case 1:16-vv-00633-AOB Document 121 Filed 10/02/23 Page 2 of 10
special master issued a decision denying entitlement, finding petitioner failed to
adequately demonstrate she suffered from GBS. Petitioner filed a timely motion
for review. For the reasons discussed herein, the Court finds the special master’s
decision was not arbitrary, capricious, an abuse of discretion, or otherwise contrary
to law. Accordingly, the motion for review is DENIED and the decision below is
SUSTAINED.
BACKGROUND
Petitioner received a seasonal influenza vaccination on November 6, 2013.
According to her hearing testimony, annual flu shots were a condition of petitioner’s
employment as a respiratory therapist. Six weeks later, on December 17, 2013,
petitioner presented at the emergency room with severe lower back pain. She was
prescribed a muscle relaxant and pain medications and discharged the same day with
the following diagnosis: “Sprain of lumbosacral (joint) (ligament).” See ECF 7-3 at
29. Between December 18-24, 2013, petitioner had several follow-up appointments
with her primary care doctor. Initially attributing petitioner’s back pain to
musculoskeletal sprain, a magnetic resonance imaging (MRI) scan revealed an
angular tear/herniated disc and a slight vertebra misalignment. Petitioner was
administered and prescribed additional medications for her back pain and referred to
a neurosurgeon.
On December 27, 2013, petitioner reported new symptoms to a neurologist,
including numbness, facial drooping, shortness of breath, difficulty swallowing, and
increasing weakness. In their evaluation, the neurologist noted: “My concern at this
point is that the patient has Guillain-Barr[é] [S]yndrome. This could be a reaction to
the flu shot that she received.” ECF 7-5 at 6. This was the first time a physician
raised a possible GBS diagnosis. Petitioner was immediately transported to
the emergency room and referred to the hospital’s Neuro Intensive Care Unit
(Neuro-ICU) for monitoring and a series of additional tests, including a spinal tap.
Analysis of her cerebrospinal fluid (CSF) showed a slightly elevated protein level.
Despite the concern of possible GBS, petitioner was not treated for this condition and
was discharged four days later after her symptoms largely subsided.2 Nevertheless,
petitioner’s December 31, 2013 discharge diagnoses included “[g]eneralized
weakness, possible Guillain-Barr[é] [S]yndrome.” ECF 8-1 at 69.
2 Petitioner was not prescribed the generally accepted treatment for GBS: rapid immunomodulatory
therapies (i.e., Intravenous Immunoglobulin (IVIG) or Plasmapheresis). See https://www.mayo
clinic.org/diseases-conditions/guillain-barre-syndrome/diagnosis-treatment/drc-20363006 (last visited
Sept. 13, 2023). Instead, in addition to a prescribed muscle relaxant and pain medications, she
engaged in outpatient physical therapy. During oral argument, counsel explained that while in
transport from Aurora Lakeland Medical Center in Elkhorn, Wisconsin, to Aurora St. Luke’s Medical
Center in Milwaukee, Wisconsin (i.e., an estimated distance of 41.4 miles), petitioner’s breathing
stabilized and her most concerning symptoms plateaued such that a “wait and see” approach was
adopted by hospital staff at Aurora St. Luke’s Medical Center.
2

Case 1:16-vv-00633-AOB Document 121 Filed 10/02/23 Page 3 of 10
Throughout 2014, petitioner continued to seek medical treatment from a series
of neurologists and other medical specialists for her recurring and evolving symptoms
(e.g., lower back pain, “pins and needles” sensations, weakness, fatigue). Initially,
the physicians were circumspect, leaving open the possibility petitioner had suffered
a bout of GBS. In February 2014, for example, a cardiologist noted their impressions
as follows: “Atypical chest pain and tachycardia in the setting of a recent viral
syndrome/Guillian [sic] Barr[é]. The possibility of myopericarditis needs to be
considered as does autonomic dysfunction in this clinical setting.” ECF 7-3 at 106;
but compare ECF 7-5 at 16–17 (January 23, 2014 follow-up GBS visit: “wait a week
and watch for improvement” treatment plan) with id. at 11 (January 13, 2014 medical
assessment: “very unusual” for petitioner’s current condition to align with GBS
diagnosis). When readmitted to the Neuro-ICU for “generalized progressive
weakness” on March 14, 2014, a treating physician noted petitioner’s “recent history
of GBS diagnosis which was named on clinical exam and history with concern for
respiratory compromise.” ECF 8-5 at 6. However, the neurologist expressed doubts
about the clinical diagnosis, explaining: “She may have had GBS in [sic] back in
December given the characteristics and evolution of her symptoms, nevertheless
I don’t believe this is the case at this time.”3 Id. at 4–5. Thereafter, the neurologists
who examined petitioner grew increasingly suspect of GBS and, instead, considered
fibromyalgia as a more likely diagnosis.4
In May 2014, a neurologist documented his misgivings:
I spent a lot of time explaining to the patient and her husband that
she does not have Guillain-Barr[é] or Guillain-Barr[é]-like disease.
If there was such a disease, it would have started within 10 days of
vaccination because that is when the antibodies are produced. Her EMG
study would have been abnormal. She would have lost her reflexes, so
there is no evidence that she had that. Therefore, I cannot tell them why
she had this disease with paralysis of the arms and legs.
ECF 19-1 at 5. Over the next several months, petitioner was diagnosed with
subjective generalized muscle weakness and the treating neurologists continued
questioning the basis for any GBS diagnosis. See, e.g., ECF 9-1 at 24, 68.
3 During her March 2014 hospital stay, petitioner underwent a second spinal tap and an
electromyography and nerve condition study (EMG/NCS); her CSF again measured a slightly elevated
protein level and her EMG/NCS results were normal. Petitioner’s post-March 2014 CSF studies were
normal.
4 Petitioner’s late-2013/early-2014 application for worker’s compensation based upon her alleged
vaccine-caused injury was denied on March 31, 2014. The neurologist who reviewed petitioner’s claim
opined: “At this time, no clear diagnosis can be made of Guillain-Barr[é] [S]yndrome.” ECF 95-7 at
54.
3

Case 1:16-vv-00633-AOB Document 121 Filed 10/02/23 Page 4 of 10
In October 2014, petitioner followed up with a neurologist who diagnosed
her as suffering from “Fibromyalgia with widespread pain, tender points, sleep
disturbance, and cognitive [symptoms] . . . .” ECF 9-2 at 57 (emphasis omitted). The
neurologist questioned the prior GBS diagnosis, noting it lacked any
“objective evidence.” Id. at 51. Thereafter, in November and December 2014,
petitioner consulted various medical professionals who consistently echoed the
fibromyalgia diagnosis. See, e.g., ECF 9-3 at 17 (repeated fibromyalgia assessment);
ECF 9-8 at 58 (chronic pain and fatigue are “likely due to fibromyalgia”). Petitioner
was eventually treated for fibromyalgia and returned to work in April 2016.
DISCUSSION
I. Standard of Review
In reviewing a Vaccine Act decision, this Court may:
(A) uphold the findings of fact and conclusions of law of the
special master and sustain the special master’s decision,
(B) set aside any findings of fact or conclusion of law of the
special master found to be arbitrary, capricious, an abuse of
discretion, or otherwise not in accordance with law and issue
its own findings of fact and conclusions of law, or
(C) remand the petition to the special master for further action
in accordance with the court’s direction.
42 U.S.C. § 300aa-12(e)(2). The Federal Circuit clarified the applicable standards of
review as follows: findings of fact are reviewed for arbitrariness or capriciousness;
discretionary rulings are reviewed for abuse of discretion; and legal conclusions are
reviewed de novo. Turner v. Sec’y of Health & Hum. Servs., 268 F.3d 1334, 1337
(Fed. Cir. 2001) (citations omitted).
II. GBS-Based Claim
Petitioner claims her seasonal flu vaccine caused her to develop GBS.5 As a
5 GBS was added to the Vaccine Injury Table effective March 21, 2017. See National Vaccine Injury
Compensation Program: Revisions to the Vaccine Injury Table, 42 Fed. Reg. 6294-01, 6295 (Jan. 19,
2017) (codified at 42 C.F.R. § 100.3(a)(XIV)(D)), as amended, 82 Fed. Reg. 11321-01, 11321 (Feb. 22,
2017) (“This document announces that the effective date is delayed until March 21, 2017.”); but cf.
Wyatt v. Sec’y of Health & Hum. Servs., 825 F. App’x 880, 884 n.2 (Fed. Cir. 2020) (“GBS was added to
the vaccine table in December 2017.”). However, the Vaccine Act specifies the version of the Table in
existence at the time a petition is filed controls. 42 U.S.C. § 300aa-14(c)(4) (“Any modification . . . of

Case 1:16-vv-00633-AOB Document 121 Filed 10/02/23 Page 5 of 10
threshold matter, the special master determined petitioner did not demonstrate
she suffered from GBS, citing her clinical presentation, CSF and EMG/NCS results,
and her treating physicians’ medical assessments and prescribed treatments.
In particular, the special master relied on the real-time, documented opinions of
petitioner’s later-treating physicians who, as noted supra, were increasingly suspect
of the preliminary (working) GBS diagnosis. Petitioner argues the special master
erred because “[t]he full medical record is fully consistent with a GBS diagnosis and
nothing else.” ECF 111 at 9. The Court disagrees.
Petitioner bears the burden to show by preponderant evidence a medically-
recognized injury. See Broekelschen v. Sec’y of Health & Hum. Servs., 618 F.3d 1339,
1346 (Fed. Cir. 2010) (appropriate for special master to first determine which injury
was supported by evidence before analyzing causation). “[I]f the existence and nature
of the injury itself is in dispute, it is the special master’s duty to first determine which
injury was best supported by the evidence presented in the record . . . .” Lombardi v.
Sec’y of Health & Hum. Servs., 656 F.3d 1343, 1352 (Fed. Cir. 2011) (identification of
petitioner’s injury is a prerequisite to causation analysis). Moreover, as explained by
the Federal Circuit:
If a special master can determine that a petitioner did not suffer the
injury that she claims was caused by the vaccine, there is no reason why
the special master should be required to undertake and answer the
separate (and frequently more difficult) question whether there
is a medical theory, supported by “reputable medical or scientific
explanation,” by which a vaccine can cause the kind of injury that the
petitioner claims to have suffered.
Hibbard v. Sec’y of Health & Hum. Servs., 698 F.3d 1355, 1365 (Fed. Cir. 2012)
(quoting Althen, 418 F.3d at 1278).
In this case, the special master made a series of factual findings based upon
a thoughtful and thorough examination of petitioner’s extensive medical records
(testing and treatment), the medical expert reports and live testimony, the
medical literature, and petitioner’s declaration and hearing testimony. Addressing
petitioner’s clinical presentation, the special master cited the following disconnects
with a typical GBS diagnosis: petitioner’s retention (and exaggeration) of reflexes; the
non-monophasic nature of petitioner’s reported symptoms; the transient
(or inconsistent) facial diplegia reportedly experienced; and petitioner’s documented
the Vaccine Injury Table shall apply only with respect to petitions for compensation under the Program
which are filed after the effective date of such regulation.”). Because the petition in this case was filed
in May 2016, the special master properly assessed this matter as an off-Table injury. See Figueroa v.
Sec’y of Health & Hum. Servs., 715 F.3d 1314, 1315 (Fed. Cir. 2013) (citing Althen v. Sec’y of Health &
Hum. Servs., 418 F.3d 1274, 1278 (Fed. Cir. 2005)). Viewed in light of petitioner’s failure to sufficiently
demonstrate she suffered from GBS, discussed infra, this issue is largely academic.
5

Case 1:16-vv-00633-AOB Document 121 Filed 10/02/23 Page 6 of 10
recovery without receiving the primary (and generally accepted) treatments for GBS
(i.e., immunotherapy). As with petitioner’s clinical presentation, the special master
found her normal EMG/NCS similarly inconsistent with a GBS diagnosis. The special
master further surmised the slight elevation in protein in petitioner’s CSF measured
following her December 27, 2013 and March 14, 2014 spinal taps–despite the reported
severity of her symptoms–was logically attributable to her recently diagnosed
angular tear/herniated disc.6
Of particular significance, petitioner never underwent immunotherapies–
the generally accepted treatment for GBS.7 Instead, nearly a year later, she was
treated for fibromyalgia, from which she recovered sufficiently to return to work in
April 2016. Related to this issue, the special master reasonably credited petitioner’s
later-treating physicians, primarily neurologists, who opined the preliminary
(working) GBS diagnosis was unsupported. Considering the potential life-
threatening (but curable) nature of GBS, it was perhaps prudent for petitioner’s
initial treating physicians–particularly those in the hospital’s emergency room–to
consider the rare disease as part of their working diagnosis.8 With the benefit of more
medical data and hindsight, however, petitioner’s treating physicians increasingly
disfavored a GBS diagnosis. Although petitioner’s symptoms subsided prior to these
later medical assessments, they did so without the benefit of GBS-targeted
treatment.
Taking the complete record into account, the special master aptly summarized
the remote possibility petitioner suffered from GBS:
6 Notably, petitioner’s treatment plan overlapped with measures generally prescribed for annular disc
tears and herniations. See https://www.ncbi.nlm.nih.gov/books/NBK459235/ (“Treatment options for
disc protrusion or herniation including conservative measures of nonsteroidal anti-inflammatory
medications, physical therapy, and local injections.”) (last visited Sept. 15, 2023).
7
Given the autoimmune nature of Guillain-Barré syndrome, its acute phase is typically treated with
immunotherapy, such as plasma exchange to remove antibodies from the blood or intravenous
immunoglobulin. See https://www.who.int/news-room/fact-sheets/detail/guillain-barr%C3%A9
syndrome#:~:text=There%20is%20no%20known%20cure,the%20blood%20or%20intravenous%20imm
unoglobulin (last visited Sept. 15, 2023).
8 Both the World Health Organization and the Mayo Clinic highlight the rarity and potential
life-threatening nature of GBS. See https://www.who.int/news-room/fact-sheets/detail/guillain-
barr%C3%A9-syndrome#:~:text=Key%20facts,cases%20of%20Guillain%2DBarr%C3%A9%20
syndrome (last visited Sept. 12, 2023); https://www.mayoclinic.org/diseases-conditions/guillain-barre-
syndrome/symptoms-causes/syc-20362793 (last visited Sept. 12, 2023).
6

Case 1:16-vv-00633-AOB Document 121 Filed 10/02/23 Page 7 of 10
Ultimately, if GBS was Petitioner’s correct diagnosis, that would
mean she is 1) among the approximately 10% of patients who do not
experience diminished reflexes; 2) among the 2-5% of patients who
do not have a monophasic course; 3) among the 4% of GBS patients who
recovered without treatment; and 4) among the approximately 1% of
patients with normal EMG results. While the co-occurrence of all these
clinical features is possible, I do not find it is more likely than not.
Viewing the medical record as a whole in light of the expert testimony
and medical literature, I find that Petitioner has not provided
preponderant evidence that she had GBS.
ECF 110 at 31–32 (internal citations omitted). Put simply, possible does not satisfy
the required standard of proof: reasonably probable. See Howard v. United States,
No. 16-1592, 2023 WL 4117370, at *4 (Fed. Cl. May 18, 2023) (“The standard
for medical proof is preponderance–not plausibility. The statute is clear in this
regard.”) (citing 42 U.S.C. § 300aa-13(a)(1)(A)). The Court therefore declines
petitioner’s invitation to reassess her medical records and expert testimony. See
Porter v. Sec’y of Health & Hum. Servs., 663 F.3d 1242, 1249 (Fed. Cir. 2011) (“We do
not reweigh the factual evidence, assess whether the special master correctly
evaluated the evidence, or examine the probative value of the evidence or the
credibility of the witnesses–these are matters within the purview of the fact finder.”)
(citing cases).
At bottom, the special master’s factual determination that petitioner failed to
meet her burden of demonstrating by preponderant evidence that she suffered from
GBS is supported by the record presented. As such, there is no basis in fact or law
for this Court to disturb that finding. In the absence of the claimed disease, there is
no viable off-Table injury to assess.
III. Fibromyalgia-Based Claim
Given the evolution of petitioner’s claim, one final issue merits discussion.
When petitioner filed this action in May 2016–2.5 years after receiving the flu shot
at issue and one month after returning to work–she referenced GBS as the initial
“impression” and “concern” upon presentation at the emergency room; however,
petitioner’s claim was based on her “ultimate diagnos[is]” of fibromyalgia. Compare
ECF 1 ¶ 5 (reference to GBS) with id. ¶ 10 (reference to fibromyalgia); see id. ¶ 12
(“Petitioner contends that she suffered Fibromyalgia which was caused-in-fact by the
vaccine of November 6, 2013.”) (citing 42 U.S.C. § 11(c)(1)(C)(ii)(I)). As noted by the
special master at the outset of her opinion, petitioner thereafter shifted her theory of
recovery from fibromyalgia to GBS without formally amending her petition.
See ECF 110 at 1–2. This change was expressly confirmed in the course of the
November 8, 2021 virtual hearing. See ECF 102 at 176–78, quoted in ECF 110 at 28.
7

Case 1:16-vv-00633-AOB Document 121 Filed 10/02/23 Page 8 of 10
More specifically, during the proceedings before the Office of the Special
Master, petitioner relegated her fibromyalgia diagnosis to the sequela of GBS. Based
upon this representation, the special master noted: “Because I have determined that
Petitioner did not have GBS, I have not analyzed whether she developed fibromyalgia
after and as a consequence of GBS.” ECF 110 at 28. In her motion for review to this
Court, petitioner maintains the same GBS-focused approach.9 Although present
during (and participating in) the virtual hearing before the special master, petitioner
was not specifically asked to confirm on the record her agreement with her counsel’s
modified litigative approach.
To flesh out this issue, in advance of oral argument, the Court directed
all counsel to be prepared to address the following: (1) the evolution of petitioner’s
initial fibromyalgia-based claim to the briefed and presented GBS-based claim;
(2) whether petitioner was consulted and consented to the amended GBS-based claim
in lieu of the fibromyalgia-based claim; and (3) whether the matter should be
remanded to the Office of the Special Master to determine in the first instance
whether the original claim of fibromyalgia is compensable under the National Vaccine
Injury Compensation Program, 42 U.S.C. § 300aa-10 et seq.10 In addressing these
issues, the Court instructed counsel to be prepared to discuss the potential
application of the Federal Circuit’s recent decision in DiMasi v. Secretary of Health
& Human Services, No. 22-1854, 2023 WL 4697122 (Fed. Cir. July 24, 2023), pet’n for
reh’g denied (Sept. 12, 2023).
During oral argument conducted on September 13, 2023, petitioner’s counsel
thoughtfully explained the GBS-based claim–noted in the original petition–was
deliberately and consistently presented throughout the proceedings before the Office
of the Special Master. According to counsel, the deliberate litigation strategy was to
use the subsequent fibromyalgia diagnosis and treatment as evidence of the initial
GBS working diagnosis, which bore the necessary temporal relationship to the
November 6, 2013 flu shot and, most significantly, explained petitioner’s December
2013 symptoms. Counsel’s representations are consistent with petitioner’s expert
9 See, e.g., ECF 111 at 1 (“[N]o alternative to GBS was established except Fibromyalgia, which is
also consistent as following from GBS or being simply long-term effects of GBS.”); id. at 9 (“The full
medical record is fully consistent with a GBS diagnosis and nothing else.”); id. at 9–10 (“[T]he GBS
diagnosis is correct . . . . The diagnosis of Fibromyalgia is based on a different stage of the same
injury.”); cf. ECF 118 at 2 (“While the Petitioner’s experts disagree whether Ms. Larson suffered from
[GBS or fibromyalgia] or both, they opine that either GBS can lead to Fibromyalgia or that the
symptoms deemed Fibromyalgia are the sequela of GBS. In either case, the injury is established.”).
10 Counsel were also advised the Court would inquire about the significance, if any, that petitioner
never underwent immunotherapy to treat her claimed GBS. Petitioner’s counsel downplayed the need
for GBS-targeted treatment in light of the near-immediate improvement in petitioner’s most severe
symptoms (i.e., difficulty breathing, facial drooping); in turn, respondent’s counsel included this item
in the laundry list of disconnects from a typical GBS diagnosis. As noted in Section II, supra, the
Court found this fact supportive of the decision below.
8

Case 1:16-vv-00633-AOB Document 121 Filed 10/02/23 Page 9 of 10
witness reports dating back to September 2017 and February 2018. See ECF 42-1;
ECF 46-1. These representations are further consistent with the parties’ pre- and
post-hearing briefing before the Office of the Special Master as well as the motion for
review pending before this Court. And, as detailed above, any conflation was clarified
during the November 8, 2021 hearing before the special master. See ECF 102 at 176–
78.
Turning to petitioner’s consultation and consent to the amended claim, her
counsel of record credibly stated: since taking over this case in May 2019, the theory
of recovery consistently has been GBS-based with fibromyalgia as the sequela of GBS.
Upon this premise, counsel explained no pointed conversation with petitioner about
abandoning (or compromising) an independent fibromyalgia-based claim took place
as it was unnecessary given the medical evidence presented and the consistent
(longstanding) litigation strategy. On this point, it is worth noting petitioner
attended (and participated in) the entire November 8, 2021 virtual hearing before the
special master when the GBS-based claim was presented, and her counsel engaged
in the exchange with the special master about the nature and scope of petitioner’s
claim. Further, review of petitioner’s hearing testimony–which focused on her
preliminary GBS diagnosis–supports finding petitioner was aware she was not
pursuing a fibromyalgia-based claim. While it clearly would have been preferable for
the special master to ask petitioner on the record if she both understood and agreed
with her counsel’s representations regarding the nature and scope of her claim, such
process is not required. Readily distinguishable from DiMasi, the facts here do not
present the rare case of gross misconduct from which petitioner should be excused
from the tactical decisions of her chosen counsel. See 2023 WL 4697122, at *8–10
(gross misconduct claim substantiated where attorney abandoned significant
aggravation claim without consulting client or seeking her consent and, thereafter,
misrepresented the special master’s decision dismissing the claim).
For these reasons, there is no basis in fact or in law to merit a remand to the
Office of Special Master to determine in the first instance whether a standalone
fibromyalgia-based claim could succeed.11
11 To this point, it is worth noting: one of petitioner’s expert witnesses opined petitioner’s fibromyalgia
evolved from the alleged GSB the special master found petitioner failed to establish, see ECF 102 at 80,
86–87, 89–90, 91–92, 105, 106–07; and petitioner’s other expert maintained petitioner never
contracted fibromyalgia related to her flu shot. See id. at 47, 61, 71.
9

Case 1:16-vv-00633-AOB Document 121 Filed 10/02/23 Page 10 of 10
CONCLUSION
For the foregoing reasons, the petitioner’s motion for review (ECF 111) is
DENIED and the decision of the special master (ECF 110) is SUSTAINED.
It is so ORDERED.
___________________
Armando O. Bonilla
Judge
10